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1. Introduction 
 
1.1    Helicobacter pylori 
 
Helicobacter pylori (H. pylori) characteristically is a gram-negative bacterium of human 
gastric. Special shape and characteristics of this bacterium lead to colonization in the human 
gastric mucosa. Helicobacter pylori results in acute inflammation, chronic inflammation and 
gastric cancer. This bacterium was first isolated in 1983. After a short time, it was reported 
that this bacterium is associated with peptic ulcer. This finding in 2005 led to Nobel prize 
(Fock et al. 2013). H. pylori infection currently influences almost 50% of the world’s 
population and it is considered as a cause of gastric and duodenal ulcer, chronic gastritis, 
gastric mucosa associated lymphoid-tissue (MALT) lymphoma, and gastric adenocarcinoma. 
People usually get the infection in childhood and they carry the infection for whole life. H. 
pylori is known for several genes and proteins which help the bacterium to be a pathogen to 
cause different diseases and epidemiological conditions. Frequency and severity of H. pylori 
could be different between different populations (Correa and Piazuelo 2008). H. pylori uses 
different ways of transmission such as oral and fecal ways. H. pylori has abilities to persist in 
the gastric and acidic situation due to special spiral form and flagella which lead to propel 
into lumen, penetration and colonization. Moreover H. pylori produces urease, an enzyme 
which produces ammonium to neutralize gastric acid. Most of the H. pylori Infections do not 
cause severe diseases and obvious symptoms, so it is left without treatment and special care 
(Thaker et al. 2016). 
 
1.1.1    Epidemiology of H. pylori 
 
H. pylori is estimated to spread from East Africa around 58,000 years ago. Currently 
childhood is the age of infection onset. H. pylori infection is more common in developing 
countries than developed countries (Linz et al. 2007). H. pylori transmission is accompanied 
by poor household sanitation and healthy conditions. The bacterium is disappearing in good 
hygienic societies with clean water and high standards of living, but remains common where 
these conditions are still missing (Aitila et al. 2019). The incidence of H. pylori shows large 
epidemiological differences. The infection positivity could vary from 80% of some 
populations to 40% of the populations with high level of sanitation and economic situation. 
The incidence of H. pylori is significantly lower in children than in adults (Genta 2002).  
 
H. pylori a permanent-colonizing bacterium, usually occurs in early childhood and lasts for 
life. H. pylori infection happens in childhood and remains persistently for the rest of life. 
“The active elimination of H. pylori from the population with enhanced hygiene and housing 
conditions resulted in a lower infection rate in children, which reflects the infection age of H. 
pylori in the childhood and persistence for life” (Kusters et al. 2006). 
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Figure 1. Global prevalence of H. pylori. Frequency of H. pylori across the world shows high 
frequency in developing countries and low frequency in industrialized countries (Zamani et al. 2018; 
K. Y. Hooi et al. 2017). 
 
1.1.2    Infection mechanisms of H. pylori 
 
H. pylori is adapted to maintain and live for a life in the acidic gastric condition. These 
bacteria have a strong adaptation to its natural habitation and they can modify their 
environment to reduce the acidity and scape of harsh situation. Whereas infection typically 
does not show symptoms, it can lead to other diseases such as gastric adenocarcinoma, 
ulcer diseases (gastric and duodenal ulcer) and MALT lymphoma. H. pylori causes a mixed 
acute and chronic inflammatory reaction, stimulating neutrophils, eosinophils, mast cells and 
dendritic cells. However, H. pylori has been considered a non-invasive pathogen, it is an 
intracellular bacterium of innate immune cells with ability of interfering with the phagosome 
maturation which could explain the difficulty in eliminating the bacteria (Diaconu et al. 2017; 
Kusters et al. 2006).  
 
 
 
 
Figure 2. H. pylori infection. H. pylori 
infection can lead to diseases such as gastric 
and duodenal ulcer, MALT lymphoma, and 
Adenocarcinoma (adapted from Diaconu et 
al. 2017). 
3 
 
1.1.2.1    Survival of H. pylori 
 
 Usually human gastric lumen is able to block all of the ingested bacteria by using natural     
defense mechanisms. Any microorganism which can have successful gastric colonization in 
gastric lumen should have various abilities to suppress host acidic conditions in the mucosal 
lumen. Acidic pH is not the optimum condition for H. pylori, however it can survive in the 
acidic condition. The ability to defeat acidic condition is largely due to production of urease 
enzyme in the bacterial cytosol and bacterial surface. Stomach with acidic condition (pH 1-2) 
is the first barrier for H. pylori survival. H. pylori can neutralize acidic condition to have a less 
acidic environment (pH 5). Many bacteria cannot live and survive in PH 5 (Robinson et al. 
2017; Scott et al. 2016). Urease sounds to be the most important H. pylori factor to survive 
in acidic condition. Urease is able to hydrolyze urea to produce ammonia, which acts as a 
receptor for H+ ions and therefore it leads to ammonium production which then creates a 
neutral microenvironment. Urease enzyme can shift gastric pH from 1-2 to 2-6 and as a 
result H. pylori can survive in the gastric condition (Figure 3) (Robinson et al. 2017; Talebi 
Bezmin Abadi 2017).  
 
1.1.2.2    Penetration of H. pylori to mucus layer 
 
H. pylori has to move into the mucus layer for colonization and helical shape of H. pylori has 
an important role in this penetration. Acidic environment can cause harm to H. pylori and 
the bacterium has to escape from gastric lumen to gastric mucus (Atuma et al. 2001). H. 
pylori can penetrate into the gastric mucosal layer with its 2 to 6 polar flagella and also 
through the production of urease, which allows it to meet friendlier environment (pH 5-6) 
(Figure 3) (Uemura et al. 2001). H. pylori mutants which have defects in helical shape are 
unable to penetrate inside the gastric mucus (Dunne et al. 2014). 
 
1.1.2.3    Adherence of H. pylori to epithelial cells 
 
Studies have shown that only a small fraction of H. pylori bacteria in gastric lumen can 
penetrate into gastric mucus and contact with the epithelial cells which is important in H. 
pylori pathogenesis (Dunne et al. 2014). H. pylori outer membrane proteins (OMP) family 
aligns with other H. pylori adhesion proteins assist in the successful binding of the bacterium 
to the epithelium. A variety of virulence factors including BabA, HorB, HomB, IceA2, AlpA, 
AlpB, DupA, OipA, SabA, HopZ, CagA, DupA and Lectin ensure the H. pylori attachment to the 
gastric epithelium. BabA is a major member of OMPs and it is one of the significant protein 
involving in the attachment for the persistent colonization. Secreted lectin by H. pylori is able 
to induce small cytoplasmic changes for the bacterial attachment to the epithelial cell 
(Kusters et al. 2006; Talebi Bezmin Abadi et al. 2015). Interestingly, although H. pylori 
adherence is mediated by surface proteins, different studies could not suggest a specific 
molecule to have the main role in the bacterial adherence (Oleastro and Ménard 2013). 
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 1.1.2.4    Injection of virulence factors to epithelial cells 
 
Clinical outcomes of H. pylori infection are associated with expression of certain H. pylori 
virulence factors such as CagA and VacA. The most known virulence factor is the cytotoxin-
associated gene A (CagA). “Following binding of H. pylori to epithelial cells the CagA protein 
is injected into the epithelial cells via a Type IV secretion system (T4SS) encoded by genes 
present on a pathogenicity island (cagPAI)” (Dunne et al. 2014). When CagA is translocated 
into the cell, phosphorylation independent pathways as well as phosphorylation dependent 
pathways are performed to undertake the infected cell signaling mechanisms. Serious forms 
of diseases are associated with CagA expressing. (Figure 3) (Dunne et al. 2014). Studies have 
shown that CagA expression can result in oncogenesis features (Bonsor et al. 2018).  
 
The H. pylori gene VacA encodes a secreted cytotoxin (VacA) which induces vacuolation in 
the host cell. VacA secretion is done by type V secretion system. The physiological 
importance of vacuolation during H. pylori infection is that vacuolation affects cell 
membranes and secretion pathways. Another function of VacA is related to mitochondria. 
VacA can enter to mitochondria to initiate apoptotic cascades (Palframan et al. 2012). VacA 
is able to induce vacuolation and also VacA is responsible to host immune response 
modulation that permits H. pylori long-term colonization (Figure 4) (Polk and Peek 2010). 
 
1.1.3    H. pylori in pancreatic cancer 
 
“Pancreatic cancer is the 14th most common cancer worldwide and it is the 7th highest 
cause of cancer mortality in the world in males and females. Pancreatic cancer has one of 
the highest mortality rates among all cancers with median survival of 3-6 months” 
(McGuigan et al. 2018). High mortality rate of pancreatic cancer indicates importance of 
early detection especially for pancreatic ductal adenocarcinoma (PDAC) which is the most 
common type of pancreatic cancer. “Europe and North America has the highest pancreatic 
cancer frequency while Africa and South Central Asia indicate the lowest frequency” (Figure 
5) (McGuigan et al. 2018). Due to lack of effective screening, most PDAC patients show 
advanced disease or metastatic. Finding new methods and strategies for PDAC detection and 
management is related to finding new risk factors by case-control and cohort studies 
(Trikudanathan et al. 2010).  
 
In the past it was confidently established that H. pylori has an important role in gastric 
diseases and gastric cancer (Marshall 1995, Correa and Houghton 2007). Some studies 
including meta-analyses suggest that H. pylori might be associated with PDAC and the 
bacterium has a role in the progression of pancreatic cancer (De Martel et al. 2008; Risch et 
al. 2010).  
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Figure 3. Colonization and infection model by H. pylori. Urease generates ammonia from urea to 
increase the pH to protect the bacteria from gastric acid. Movement of helical shaped bacteria helps 
it to enter gastric mucus and also helps to survive in the acidic situations of the lumen. Only a small 
fraction of the bacteria can attach to the epithelial cell. Outer membrane proteins (OMPs) and other 
adhesive mediators help bacteria attachment. H. pylori pathogenic factors such as CagA is injected 
into the epithelial cell by Type IV secretion system and starting CagA phosphorylation dependent and 
CagA phosphorylation independent pathways to transform epithelial cell function (adapted from 
Dunne et al. 2014). 
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Figure 4. VacA, a multi-functional toxin. VacA induces vacuolation in the host cell. VacA can release 
cytochrome c, which initiates apoptosis. VacA can cause inflammation and finally VacA blocks T-cell 
proliferation (Palframan et al. 2012).  
 
 
 
 
Figure 5. Incidence of pancreatic cancer. The age-standardized incidence shows pancreatic cancer 
frequency across the world (McGuigan et al. 2018). 
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Studies have shown antibody level against H. pylori is increased in pancreatic cancer (Bulajic 
et al. 2014). Some studies show that the risk of pancreatic cancer and autoimmune 
pancreatitis is increased by H. pylori infection (Culver et al. 2017). Moreover, numerous 
epidemiological publications also showed that patients with H. pylori infection are likely to 
have pancreatic cancer (Lindkvist et al. 2008). “Because of the small number of cases and 
different study methods, the meta-analysis results were limited and there was lack of power 
to confirm the high prevalence of H. pylori in pancreatic cancer rather than control group” 
(Wu et al. 2016). Finally people with H. pylori infection have a higher risk of developing PDAC 
(Becker 2014; Benzel et al. 2018). Different mechanisms and theories have been suggested 
to clarify how H. pylori infection causes carcinogenesis (Trikudanathan et al. 2010). 
 
First possible mechanism emphasizes in inflammation, inflammatory mediators such as CagA 
and inactivation of tumor-suppressor genes in H. pylori infections which cause malignant 
transformation in pancreas. Second possible mechanism emphasizes in IL-8, VEGF and 
nuclear factor kB. Generally, the H. pylori infection increases in inflammatory cytokine and 
angiogenic factor secretion, ending in malignant transformation of the pancreatic cell line 
(Takayama et al. 2007). Third possible mechanism emphasizes in H. pylori colonization after 
decreases in gastrin and gastric acid.  Gastrin is important in gastric acid production. This low 
acidity assists bacterial growth and increases production of N-nitroso (Annibale et al. 2002). 
 
1.2    Herpesviridae family  
 
“Herpesviridae family has evolved 180–220 million years ago and the present study 
highlights that it is still evolving and more genes can be added to the repertoire of this 
family” (Sehrawat et al. 2018). Herpesviridae family members have double strand DNA in 
nucleocapsid which is covered by tegument. The tegument is then covered by virus envelope 
which consists of a lipid membrane and glycoproteins (Figure 6). Herpesviruses are able to 
attach and penetrate to host cells. After releasing of viral DNA inside the host cell, 
transcription and translation of viral genes are performed. DNA replication is done by rolling 
circle mechanism in the nucleus of the host cell and after viral assembly and packaging, new 
virions release to outside by exocytosis mechanism (Figure 7). Herpesviridae family is 
considered as DNA viruses which consist of major pathogens with an extensive range of 
hosts. “Herpesviridae family has zoonotic potential thus they are responsible for a broad 
range of diseases in humans and animals” (Wozniakowsk and Salamonowicz 2015). 
Herpesviridae family includes nine types of viruses which can cause human infection: herpes 
simplex viruses (HSV), Varicella zoster virus (VZV), Epstein Barr virus (EBV), human 
cytomegalovirus (CMV), human herpesvirus 6, 7 and Kaposi's sarcoma-associated 
herpesvirus (KSHV). So far more than 130 herpesviruses from mollusks, birds, fish, reptiles, 
amphibians and mammals have been known (Brown and Newcomb 2011). 
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Figure 7. Life cycle of herpesviruses. 1. Herpesviruses move into host cells following attachment and 
penetration. 2. Releasing of viral DNA inside the host cell. 3. Transcription and translation (A, B). 4. 
DNA replication machinery in the nucleus of the host cell. 5. Virus association. 6. Assembling and 
maturation. 7. Budding. 8. Final maturation inside the cell. 9. Exocytosis of the virion (Zimmerli 2005, 
P. 44). 
 
1.2.1    Herpesviridae family classification 
 
“The subfamilies of Herpesviridae family are classified based on their cytopathic effect, 
replication strategies, genetic organization and hosts into alpha (α), beta (β), and gamma (γ) 
Figure 6.  Structure of herpesviruses. 
The tegument surrounds the 
nucleocapsid containing the double 
stranded DNA. A lipid bilayer 
membrane covered by glycoproteins 
forms the virus envelope (Zimmerli 
2005, P. 43). 
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subfamilies” (Table 1) (Whitley 1996). Among 130 herpesviruses, Cytomegalovirus, HSV 1, 2, 
Epstein Barr and Varicella zoster are example of herpesviruses can cause diseases in humans 
(Boshoff and Weiss 2001; Virgin 2014). 
 
Table 1. Classification of Herpesviridae family. Herpesviridae family is categorized into three 
subfamilies in the basis of cytopathic effect, host range, genetic material and replicative cycle 
(Adapted from Whitley 1996). 
 
1.2.2    Infection mechanisms of herpesviruses  
 
Following a primary exposure, herpesviruses can live and maintain in appropriate hosts for a 
long time mainly because of having the latency and the lytic cycles and also having the ability 
for immune system evasion which make herpesviruses successful pathogens (Uppal et al. 
2014; Virgin 2014). As they have zoonotic potential to cross infection between species; 
infection in non-native hosts could result in more severity. HSV infection in mice (non-native 
host) is highly virulent and cause lethal encephalitis, a very rare outcome in humans. 
“Another example is herpes B virus, α-herpesvirus of monkeys causes lethal encephalitis in 
humans” (Wozniakowski and Samorek-Salamonowicz 2015). 
  
1.2.3    Immune system evasion of herpesviruses 
 
Herpesviruses have the ability of immune system evasion and immune system decrease by 
using latency phase and using immunomodulatory mechanisms which allows lowest immune 
recognition (Rezaee et al. 2006; Hengel et al. 1997). Herpesviruses are host immune 
modifiers (Litjens et al. 2018).  
 
1.2.4    Turkey herpesvirus (HVT)  
 
Turkey herpesvirus (HVT) is also called as the third serotype of the Marek’s disease virus 
(MDV), is one of the alpha herpesviruses. HVT could be defined as an abundant virus in 
domestic turkeys and almost a nonpathogenic virus. MDV group is avian herpesviruses with 
an affinity to lymphocytes. MDV serotype 1 (MDV1) is the cause of the Marek’s disease in 
chickens which brings economic problems. “HVT is nonpathogenic in chickens, but it does 
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induce a viremia which is associated with induction of protective immune responses against 
MDV1” (Witter 1997). So far there is no report regarding detection of HVT in human beings. 
 
1.2.5    HVT Pathogenicity 
 
HVT is non-pathogenic for turkeys. In chickens, HVT does not lead to tumorigenesis, but 
other problems have been observed (Witter et al. 1970). Some evidences such as induction 
of wounds and lesions in the chickens emphasize in HVT transformation ability (Purchase 
and Sharma 1974; Prasad 1979). Unpublished data in our division including the Next-
generation sequencing result, digital PCR and real-time PCR confirms that HVT associates 
with PDAC (Mohan 2015, P. 49).   
 
1.3    Cell-free protein microarray as a powerful technology for antigen 
screening    
  
Cell-free protein microarray is a strong and pioneering technology for the detection of 
positive candidates, novel biomarkers and protein-antibody reactivities. Protein purification 
is expensive and time-consuming and could destroy the protein structure and function. Cell-
free protein microarray technology avoids protein purifications by replacing expression in 
situ with an in vitro transcription-translation. This technology allows doing high-throughput 
approaches for the analysis of the proteome at large scales (Merbl and Kirschner 2010). In 
comparison to other proteomics methods, cell-free protein microarray avoids the necessity 
of purification a sample into small parts and therefore complex samples can be immediately 
applied for research (Hanash 2003). 
 
In the cell-free protein microarray, proteins are produced from a template which has the 
regulatory sequences for in vitro transcription and translation. Then the new synthesized 
protein is captured by affinity reagents (Díez et al. 2015). In our method the DNA template is 
an expression construct with His-Tag and V5-Tag which is flanked by regulatory sequences, 
made by two successive PCRs and after in vitro transcription-translation, nascent protein 
binds to Ni surface by His-Tag. In this thesis H. pylori whole-proteome microarray and HVT 
whole-proteome microarray were produced from H. pylori ORFeome and HVT ORFeome. 
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1.4    Aims of the project 
 
After generation of H. pylori whole-proteome microarray and HVT whole-proteome 
microarray the aim of this study was to identification of potential biomarkers for H. 
pylori-associated PDAC and HVT-associated PDAC. The long-term goal of this project is 
finding diagnostic biomarkers for PDAC detection purposes.  
 
Overall aims of this project are: 
 
 Detection of H. pylori-associated antigens to PDAC. 
 Detection of HVT-associated antigens to PDAC. 
 Identification of H. pylori-associated antigens for diagnostic purposes. 
 Identification of HVT-associated antigens for diagnostic purposes.
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         2.    Materials and Methods 
2.1    Chemicals and labwares 
Table 2. Chemicals and labwares used during this thesis 
 
Product Company Catalog number 
 
6x DNA Loading dye Fermentas R0611 
 
Adhesive PCR plate foil Thermo Scientific AB0626 
 
Microcentrifuge tube 1.5 ml Eppendorf 0030120086 
 
Microcentrifuge tube 2 ml Eppendorf 0030120094 
 
GeneRuler 1 kb DNA ladder Thermo Scientific SM 0311 
 
XCEED Nitrile Exam Glove Microflex 108-60299 
Nickel sulfate Sigma-Aldrich 227676 
Nickel nitrilotriacetic acid Sigma-Aldrich 72560 
 
Nuclease-free water Life Technologies AM9939 
 
NAP-Blocker G-Biosciences 786-190S 
 
PCR tubes,8 strip 0,2 ml Life Technologies AM12230 
 
Sodium chloride Sigma-Aldrich S9888 
 
Sodium phosphate dibasic Sigma-Aldrich S9763 
 
SuperBlock blocking Buffer Thermo Scientific 37515 
 
                             PCR plate, 96-well, non-skirted               Thermo Scientific                AB0600L 
                             Blocking solution                              Candor bioscience               110 050 
                             Betaine                                                        Sigma-Aldrich                            61962 
                             Pipettes tips Biozym 720031, 720230, 721014 
Nexterion Block E SCHOTT 1066069 
Glacial Acetic Acid Sigma-Aldrich A6283-1L 
Potassium phosphate monobasic Sigma-Aldrich P9791-500G 
dNTPs Genaxxon M3015.4100 
                           Microplate, 384 Well, Pp, V-Bottom     Greiner                                         781280 
Epoxysilane slide                                        Schott                                            1066643 
Milk powder                                               Bio RAD                                        1706404 
ProPlate®   Multi-Well   Chambers        Graco Bio-Labs                      246861  
Well Slide Module delrin clip 
Agarose  BioReagent,  for  molecular       Sigma-Aldrich                                 A9539-500G 
biology, low EEO 
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2.2    PCR reagents and expression kits 
 
Table 3. Kits and enzymes used in this thesis 
Product  Company                     Catalog number 
 
                           QIAamp DNA Mini Kit/for isolation of                         Qiagen                              51304 
                          bacterial and viral genome 
                          Qiagen Long Range PCR kit                                           Qiagen                              206403 
                          S30 T7 High-Yield Protein Expression Kit               Promega                   L1110 
                          Taq DNA Polymerase                                                     Qiagen 201207 
 
 
2.3    Antibodies 
 
Table 4. Source of antibodies used 
 
                           Product                                                              Company                                         Catalog number
Alexa Fluor-647 AffiniPure Goat    
Anti-Human IgA+IgG+IgM (H+L) 
  Jackson ImmunoResearch 109-605-064 
 
Monoclonal Anti-V5, Cy3 conjugate   Sigma-Aldrich V4014-100UG 
Penta-His Alexa Fluor-647 Conjugate   Qiagen 35370 
 
 
2.4    Buffers and media 
 
50xTAE buffer:
                           Tris Base 242 g 
Glacial Acetic Acid 57.1 ml 
0.5 M EDTA 100 ml 
ddH2O Up to 1000 ml 
 
 
 
10xPBS:  
Tris Base 242 g 
NaCl 80 g 
KH2PO4 2 g 
Na2HPO4 11.1 g 
ddH2O Up to 1000 ml 
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1xPBST:  
10xPBS 100 ml 
10% Tween-20 5 ml 
ddH2O Up to 1000 ml
 
 
1% Agarose gel:                              
                          1xTAE buffer 200 ml 
Agarose 2 g 
 
 
2.5    Equipments 
 
Table 5. Source of equipments  
Name Company 
 
Gel Documentation System Azure Biosystems 
 
Heating Block Grant Instrument 
 
Ice maker Scotsman 
 
Laminar Hood Hereaus instruments 
 
Microcomputer electrophoresis power supply Renner GmbH 
 
Microwave oven Bosch 
 
Mixmate Microplate Mixer                                      Eppendorf 
Nanoplotter 2.1 GeSIM 
Orbital Shaker Edmund Bühler 
 
PowerScanner Tecan 
 
Thermocycler LifeEco 
 
TKA MilliQwatter supply Millipore 
 
Ventillated oven Kendro Instruments 
 
Vortex Mixer Neolab 
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2.6    DNA extraction 
 
H. pylori genomic DNA was supplied by ATCC (ATCC™, 700392D-5) as pure genomic DNA but 
for HVT (ATCC™, VR-584B) there was not any source of DNA. After ordering the virus I 
received cell pellet and supernatant. Since it was not known if this virus would be present in 
the cell pellet or in the supernatant, DNA extraction was performed using both supernatant 
and cell pellet and results were confirmed by PCR. For this purpose, very specific forward 
and reverse primers were designed which just amplified HVT sequence (HVT075) and the 
primers didn’t amplify any other viruses or organisms. 
Table 6. Forward and reverse primers used for HVT confirmation 
 
Forward primer        5´-AAGTGGGCGTGCAATGATAC-3´ 
Reverse primer         5´-TCTTCACACACGCCCTGTAT-3´ 
 
 
2.7    Primer design and strategy 
For primer design all of the open reading frame (ORF) sequences were extracted from 
databases. Each ORF starts with ATG codon and ends at stop codons. To have an expression 
construct each ORF should be in frame and stop codons should be removed from the 
sequence. Forward primer starts at the ATG codon and reverse primer starts at the end of 
the ORFs. To have the best PCR result every primer has the length of 16-23 nucleotides, 50% 
GC content and 50°C Tm. Then binding specificity of each primer was checked by blast tools. 
Because of different GC content at the beginning and at the end of a gene, primer designing 
with the similar criteria was not always possible and also in cell-free protein expression 
technique there are some difficulties in expression of ORFs more than 5 kb, therefore with 
splitting a gene into two or three smaller sections it was possible to have a better primer 
design for PCR and also to be sure about full protein expression. Splitting a gene can result in 
missing natural protein structures which by sequence overlapping it is possible to overcome 
this problem to some extent. H. pylori primers were designed already by HUSAR (Heidelberg 
Unix Sequence Analysis Resources) and I designed HVT primers in our laboratory. For these 
purpose I used different databases and tools (Table 7). Moreover, these specific primers 
were flanked by 2 overhangs which then used for binding sites of primer pairs in the second 
PCR. In the second PCR regulatory sequences for transcription and translation were added 
by using second primers.  
Table 7. Name of databases and tools for primer design 
 
Name                                         Address 
NCBI                                                              https://www.ncbi.nlm.nih.gov 
NCBI blast                                                     https://blast.ncbi.nlm.nih.gov/Blast.cgi 
Primer3                                                         http://primer3.ut.ee/ 
In Silico PCR                                                  http://rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr 
OligoCalc                                                       http://biotools.nubic.northwestern.edu/OligoCalc.html 
Integrated DNA Technology                        https://eu.idtdna.com/site/account/ 
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Table 8. Overhangs primers 
 Forward primer overhang   5’-ATGCACCAAACCCAA-3’ 
 Reverse primer overhang    5’-CGCACTGGCATCATC-3’ 
 
Table 9. Second primer sequences used to generate expression construct 
Forward primer 5’-gaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaaga           
                                                     aggagatatacatatgcatcatcatcatcatcatatgcaccaaacccaa-3’   
             Reverse primer 5’-ctggaattcgcccttttattacgtagaatcgagaccgaggagagggttagggataggcttacccgc          
                                                      actggcatcatc-3’ 
 
 
2.8    PCR protocols  
 
For generating of whole-proteome microarray first step is to produce expression constructs. 
For this purpose, two successive PCRs by using specific primers for the first PCR and common 
primers for the second PCR were performed. For PCR products more than 1 kb length, Long 
Range Enzyme (Qiagen) was used instead of Taq DNA polymerase (Qiagen). First PCR 
products were used as the templates for the second PCRs to generate the final library which 
were used to produce whole-proteome microarray. Second primers bind to the overhang 
sequences in upstream and downstream of the first PCR product. Second primers include 
regulatory sequences: T7 promoter (Pro), 5’ untranslated region (UTR), ribosome binding 
site (RBS), start codon, 6xHis-Tag, V5-Tag and T7 terminator (Ter) to each ORF.  
 
 
Figure 8. Generation of expression construct by two successive PCRs. PCR plan for generating of H. 
pylori ORFeome and HVT ORFeome with using gene specific primers (dark blue) which binds 
specifically to the beginning and to the end of the ORF (light blue). First primers also have overhangs 
(black) which used as the binding sites for the second primers. The product of the first PCR is used as 
the template for the second PCR. In the second PCR the regulatory sequences for transcription and 
translation (green and red), which are in the second primers, are added to the ORF.    
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First PCR reaction and program were prepared according to the following protocols:  
 
First PCR reaction mixture: 
PCR buffer 10x                          2 µl 
DNase-free water                          8.25 µl
                          dNTPs 10 mM                          1 µl 
                          MgCl2 25 mM                                                       2.5 µl
Betaine 5 M                          2 µl 
Forward primer 10 µM                          1 µl 
Reverse primer 10 µM                          1 µl 
H. pylori/HVT DNA 1 ng                          2 µl 
Taq DNA polymerase                          0.25 µl 
Total                                                                      20 µl
First PCR Program: 
Initial denaturation 94°C 2 min 
Denaturation 94°C  30 s 
Annealing 45-60°C 30 s 30 cycles 
Extension 72°C 3 min 
Final extension 72°C 10 min 
Hold 10°C ∞
 
Second PCR reaction and program were prepared according to the following protocols:  
 
Second PCR reaction mixture: 
PCR buffer 10x                           5 µl 
DNase-free water                           23.5 µl 
                           dNTPs 10 mM                           1 µl 
                           Betaine 5 M                                                5 µl 
Forward primer 10 µM                           1 µl 
Reverse primer 10 µM                           1 µl 
First PCR product                           2 µl 
Taq DNA polymerase                           0.5 µl 
Total 50 µl
Second PCR program: 
Initial denaturation 94°C 2 min 
Denaturation 94°C 30 s 
Annealing 50°C 30 s 30 cycles 
Extension 72°C 3 min 
Final extension 72°C 5 min 
Hold 10°C ∞ 
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2.9    Positive controls 
 
To generate whole-proteome microarray and evaluation the expression assay and 
immunoassay, positive PCRs were used which they have known expression constructs and 
after spotting and incubation, the expressed protein was used as endogenous positive 
control. P18 capsid antigen of Epstein-Barr-Virus (EBV) and F11 capsid antigen of Poliovirus 
were used as templates for Positive PCRs. Epstein-Barr-Virus DNA was in B070 laboratory 
library and Poliovirus F11 sequence was ordered as the template to be synthesized. Gene 
specific primers were designed for the First PCR. Second primers which include regulatory 
sequences for all of the expression constructs were used for the second PCRs.  
 
2.9.1    EBV p18 positive control 
 
EBV p18 control PCRs produced by the following protocols:  
 
Table 10. Forward and reverse primers used for EBV p18    
 
EBV p18_F                              5´- ATGGCACGCCGGCT-3´ 
EBV p18_R                              5´- CTGTTTCTTACGTGCCCCG-3´ 
 
First PCR reaction mixture for EBV p18:  
Buffer 10x                                                             2.5 µl 
Betaine                                                                  5 µl 
dNTP 10 mM                                                        1 µl 
MgCl2 25 mM                                                       2 µl 
Forward primer 10 µM                                      1 µl  
Reverse primer 10 µM                                       1 µl 
EBV DNA 1 ng/µl                                                 2 µl 
Taq DNA polymerase                                         0.25 µl 
DNase-free water                                               10.25 µl 
Total                                                                      25 µl 
Second PCR reaction mixture: 
PCR buffer 10x 5 µl 
DNase-free water                           23.5 µl 
                           dNTPs 10 mM                           1 µl 
                           Betaine 5 M                                                5 µl 
Forward primer 10 µM                           1 µl 
Reverse primer 10 µM                           1 µl 
First PCR product                           2 µl 
Taq DNA polymerase                           0.5 µl 
Total                                                                       50 µl 
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First PCR program for EBV P18: 
Initial denaturation 94°C 2 min 
Denaturation 94°C 30 s 
Annealing 51°C 30 s 30 cycles 
Extension 72°C 30s 
Final extension 72°C 5 min 
Hold 10°C ∞ 
 
Second PCR program: 
Initial denaturation 94°C 2 min 
Denaturation 94°C 30 s 
Annealing 50°C 30 s 30 cycles 
Extension 72°C 3 min 
Final extension 72°C 5 min 
Hold 10°C ∞ 
 
2.9.2    Poliovirus F11 positive control 
 
First PCR primers and protocols for Poliovirus F11 positive control were prepared according 
to the following protocol. Second PCR reaction mixtures and programs for Poliovirus F11 are 
the same as EBV p18. 
 
Table 11. Forward and reverse primers used for Poliovirus F11 
 
                           Polio F11_F                       5´- AAGGAAATTCCAGCACTC -3´ 
 Polio F11_R                       5´- TGTGGCCCCAGTTTCCA -3´ 
 
Table 12. Poliovirus F11 sequence to be synthesized as the template for PCR 
 5´-AAGGAAATTCCAGCACTCACCGCAGTGGAAACTGGGGCCACA-3´ 
 
First PCR reaction mixture for Poliovirus F11:  
PCR buffer 10x                                                     2 µl 
DNase-free water                                                9.8 µl 
dNTPs 10 mM                                                      1 µl 
MgCl2 25 mM                                                      2 µl 
Betaine 5 M                                                      2 µl 
Forward primer 10 µM                                       1 µl 
Reverse primer 10 µM                                        1 µl 
Taq DNA polymera                                              0.2 µl 
Polio DNA 1 ng/µl                                                 1 µl 
Total                                                                       20 µl 
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2.10    Agarose gel electrophoresis 
 
All of the PCRs were performed using 96 well plates and the Thermocycler (MJ Research 
LifeEco) and they were stored in -20°C for quality control and spotting. Quality and length of 
the final PCR products were always verified with gel electrophoresis using 1% agarose gel in 
TAE buffer. After each PCR the success of PCRs was checked by Agarose Gel Electrophoresis. 
For this purpose, 1 gram of Agarose powder (Biozyme) was dissolved in 1X TAE buffer by 
heating then it was poured in a special cast to cool down to form a gel. 5 µl of PCR products 
and 1 µl of 6X DNA Loading dye (Fermentase) were mixed and loaded on the gel. Beside that 
to check the size of the PCR products, 5 µl of 1 kb DNA ladder (Thermo Scientific) was loaded 
on the gel. The electrophoresis was performed by using the Microcomputer electrophoresis 
power supply system (Renner GmbH) at 100 Voltage for 30 minutes. Gel documentation was 
performed by Gel Documentation System (Azure biosystems) at UV 302 nm, 5 seconds 
exposure. 
 
2.11    Ni-NTA slides preparation 
 
To generate Ni-NTA slides, the epoxysilane slides were treated with a mixed solution of 0.63 
M NTA and 2.38 M sodium bicarbonate for overnight (12 hours). Then, the slides were 
washed twice with Millipore water and air-dried. Subsequently, the slides were immersed in 
NiSO4 solution for 6 hours, and then washed again. The slides were finally treated with 0.2 M 
acetic acid, 0.2 M CaCl2 and 0.1% Tween-20 for 30 minutes, washed again, air-dried and 
stored at 4°C. All steps were done under sterile hood. 
 
2.12    Spotting of protein microarrays 
 
After two successive PCRs, H. pylori ORFemoe and HVT ORFeome were generated. These 
products are expression constructs and they have sequence of gene of interest flanked by 
regulatory sequences which are necessary for transcription and translation. 45 µl of each PCR 
product was combined with 5 µl of 5 M betaine then tranfered into 384-well plates 
(Whatman). All of the samples were spotted using the Nanoplotter 2.1 (GeSIM). The spotter 
system and pins were washed once with 1% Hellmanex and twice with miliQ water for at 
least 20 minutes before and after of each spotting to prevent pin blockage and to keep the 
spotter clean. Then Z-Values were measured for all of the slides to estimate the position and 
distance of each slide. A transfer file which has all the commands and information of spotting 
were prepared in Notepad. 1.2 nl of the PCR products as two droplets were first spotted on 
the slide. Before each spotting the sample uptake was checked and confirmed by 
stroboscope automatically. In the meantime of spotting, S30 T7 High-Yield Protein 
Expression mix (Promega) was prepared as follows for 5 slides: 
 
S30 Premix Plus:                                         20 µl 
T7 S30 Extract:                                             18 µl 
Nuclease free water:                                  12 µl 
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The mixture should be homogenized while avoiding any bubble formation. 4.8 nl of the 
expression mix was then spotted on the exact same locations where the PCR products were 
spotted. Afterwards in order to allow on-chip protein expression, the slides were placed in a 
humidified incubation chamber containing 30 µl nuclease free water at each chamber 
reservoir. Then all of the slides were placed in incubation boxes containing wet tissue and 
incubated at 37°C, 50% humidity for 1 hour, and subsequently at 30°C, 50% humidity for 12 
hours in ventilated oven. After 12 hours incubation the slides were transferred into a slide 
rack and then kept at -20°C for 24 hours. 
 
Figure 9. Overview of spotting and expression of H. pylori and HVT proteins. All of the ORFs of HVT 
and H. pylori which produced by two successive PCRs are ready for spotting and expression. In the 
first step of spotting, Nanoplotter spots all of the second PCR products on slide. In the second step 
of spotting transcription and translation mixes are added on the spots. After rehydration and 
incubation, the ORFs are transcribed and translated into proteins to have a whole-proteome array. 
Finally, the expressed proteins are used for detection. 
 
2.13    Expression assay and immunoassay 
 
After producing protein microarrays, the existence of the expressed protein was checked by 
performing expression assay and after that, the reactivity of these expressed proteins on the 
array was checked with serum antibodies of cancer donors as well as cancer free donors by 
immunoassay. 
2.13.1    Expression assay 
After spotting and incubation the protein microarrays were produced and the expressed 
proteins on the array should be checked in terms of quality of protein expression. The 
presence of the N-terminal 6xHis-Tag and a C-terminal V5-Tag as fusion tags allows testing 
the expression of H. pylori and HVT antigens. For this purpose, Anti-V5 antibody (Cy3 
conjugated, Sigma) and anti-His antibody (Alexa Fluor-647 conjugated, Qiagen) with green 
and red signals respectively were applied during expression assay (Table 13 and Figure 10).  
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Table 13. Procedures of expression assay for protein microarray 
 
Expression assay  
 
 
1. Preparing fresh blocking buffer: 2% BSA in 1X PBST.  Adding 0.2 g BSA in 10 ml 1X PBST, vortexing it to 
dissolve.  Then adding 2 ml of the blocking buffer on each slide on an orbital shaker at 50 rpm speed at 
room temperature for 1 hour incubation. 
 
2. Decanting the supernatant and washing twice with 2 ml 1X PBST, each wash is 5 minutes on an orbital 
shaker at 50 rpm speed at room temperature. 
 
3. Preparing and adding 1 ml of antibody dilution (1:1000) for each slide. 1 µl of anti V5 sigma (cy3, 
Green, 532nm, V4014/100UG) and 1 µl of anti penta His, Qiagen (Alexa Flour 647, 635 Red) in 1 ml of 
the blocking buffer. Putting it on an orbital shaker at 50 rpm speed at room temperature for 1 hour 
incubation. 
 
4. Removing the slide from the chamber and washing with 6 ml 1X PBST 3 times and each wash for 10 
minutes on an orbital shaker at 50 rpm speed at room temperature for 1 hour incubation. 
 
5. Rinsing the slides in Millipore water until the spots on the slide become visible. 
 
6.  Drying the slides in a ventilated oven at 30°C for 15 minutes. 
 
7. Acquiring microarray image using Tecan PowerScanner at the wavelength of 532 nm (cy3) and 635 nm 
(Alexa Flour).
 
 
2.13.2    Immunoassay 
 
After detection of the expressed protein on the array, immunoassay was performed using 
serum samples from healthy, chronic pancreatitis (CP) and pancreatic ductal 
adenocarcinoma (PDAC) patients. The serum samples should consist 3% of the serum 
dilution and 45 µl serum was used for each slide. Pooled sera were prepared by mixing 9 µl 
of each 5 individual serum samples to a total 45 µl serum for one slide. E. coli antibodies 
which are common in human sera were neutralized by using E. coli wildtype lysate (BL21) in 
the serum dilution to have a minimum background. In principle, the specific antibody from 
the serum sample binds to the spotted pathogen candidates on the array.  If there is specific 
antibody against proteins of H. pylori, the antibody binds to the protein on the microarray 
and this binding is detected by using a secondary antibody which is conjugated to Alexa Flour 
fluorescence dye with red signal and secondary antibody binds to Fragment crystallizable (Fc) 
region of IgA, IgG and IgM (Table 14 and Figure 10). 
 
2.14    Image acquisition 
 
After immunostaining, the slides were transferred to Tecan PowerScanner for intensity 
measurement. For expression assay signals from Cy3 and Alexa Fluor-647 fluorescent dyes 
were captured using 532 nm and 635 nm excitation wavelengths respectively. For 
immunoassay signal from Alexa Fluor-647 fluorescent dye were captured using 635 nm 
excitation wavelength. The laser intensity was kept at 75% and autogain was generally used 
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for the gain setting. The scanner was in general configured with a 40 µm resolution and a 
high scanning speed setting over high sensitivity. All slide images were collected as 2200 
pixels by 7500 pixels TIFF file for further analysis. 
 
Table 14. Procedures of immunoassay for protein microarray 
 
Immunoassay 
 
1. Preparing 1.5 ml serum dilution with E. coli lysate, and blocking buffer: 45 µl of serum + 1383 µl 
blocking buffer + 72 µl E. coli lysate (20 mg/ml) and incubate it for 2 hours in 4°C. The main blocking 
buffers used in this thesis are SuperBlock buffer (Thermo Scientist) and Candor Blocking Solution 
(Candor bioscience).  
 
2. Gently adding 2 ml of blocking buffer to the slide and putting the slide on an orbital shaker at 50 rpm 
speed at room temperature for 1 hour incubation.  
 
3. Decanting the supernatant and wash twice with 2 ml 1X PBST, each wash 5 minutes on an orbital 
shaker at 50 rpm speed at room temperature.  
 
4.    Adding the 1.5 ml diluted serum dilution to the slides and putting them on an orbital shaker at 50 rpm 
speed at room temperature for 1 hour incubation.  
 
5. Decanting the supernatant and washing twice with 2 ml 1X PBST, each washing 5 minutes on an orbital 
shaker at 50 rpm speed at room temperature.  
 
6. Preparing and adding 1.5 ml of secondary antibody which is 4.5 µl of goat anti-human IgG, IgA, IgM 
Antibody (Jackson ImmunoResearch) in 1.5 ml of the blocking buffer. Putting them on an orbital 
shaker at 50 rpm speed at room temperature for 1 hour incubation. 
 
7. Removing the slide from the chamber and washing 3 times with 6 ml 1X PBST, each wash for 10 
minutes on an orbital shaker at 50 rpm speed at room temperature for 1 hour incubation.  
 
8. Rinsing the slides in Millipore water until the spots on the slide become visible. 
 
9.               Drying the slides in a ventilated oven at 30°C for 15 minutes. 
 
10.             Acquiring microarray image using Tecan PowerScanner at the wavelength of 635 nm. 
 
 The liquid amount was used for one slide. In case of dividing one slide into eight blocks, all the 
amounts should be divided respectively.
 
 
 
24 
 
 
 
Figure 10. Overview of cell-free protein microarray for antigen detection. After spotting and 
incubation, whole-proteome on the array is used for checking the expression, which is called 
expression assay by using conjugated antibody with Alexa Fluor-647 and Cy3 against His-Tag and V5-
Tag respectively. Whole-proteome also used for serum antibody reactivity, which is called 
immunoassay. In immunoassay if there is any reactivity between serum antibody and expressed 
protein on the array, this reactivity can be detected by using secondary antibody conjugated with 
Alexa Fluor-647 with red signal but in saturated condition it shows white signal. 
 
2.15    Data analysis and statistics 
 
All TIFF images were analyzed using GenePix Pro 6.0 and gal.file, which represents the order 
and position of each protein on the array and after analyzing, the quantitative data were 
extracted. After processing the Median Fluorescence Intensity (MFI) was collected. For 
comparison of Ni and Epoxy surface, Signal to Noise Ratio (SNR) was used, which considered 
Foreground signal (F), Background signal (B) and Standard deviation (SD) of the Background. 
While a protein has a MFI larger than the cut off (Average of negative MFIs + 2.5 SD of 
negatives) it is considered as a positive candidate. Statistical analysis was performed using 
GraphPad Prism 6 and Microsoft Excel 2010. A provisional Odds Ratio (OR) to compute the 
corresponding 95% Confidence Interval (CI), was calculated to estimate the importance of 
each antigen. Online databases and analytical tools for further analysis were mentioned in 
Table 15. 
 
Table 15. Databases and analytical tools for data analysis 
 
 Name                                                                            Address 
  NCBI                                                                              https://www.ncbi.nlm.nih.gov/ 
  The Human Protein Atlas                                          https:// www.proteinatlas.org/ 
  The GeneCards human gene databases                 https://www.genecards.org/ 
  Uniprot                                                                         https://www.uniprot.org/ 
  Kyoto Encyclopedia of Genes and Genomes         https://www.genome.jp/kegg/ 
  Stand protein BLAST                                                  https://blast.ncbi.nlm.nih.gov/  
  MEDCALC                                                                     https://www.medcalc.org/index.php/ 
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3.   Results 
 
3.1    HVT DNA extraction and PCR confirmation  
 
H. pylori genomic DNA was provided as a pure genomic DNA, but for HVT there was not any 
source of pure DNA. Since it was not known if this virus would be present in the cell pellet or 
in the supernatant, DNA extraction was performed using both supernatant and cell pellet 
and results were checked by PCR. For this purpose, specific primers were designed to 
amplify a short sequence of HVT (HVT075) while these primers did not bind to any DNA of 
other viruses or organisms. After DNA extraction there were two sources of extracted DNA, 
DNA from the supernatant and DNA from the cell pellet. PCRs were performed at the same 
condition by using the same amount of DNA from the supernatant and the cell pellet for 
templates. PCR results confirmed existence of HVT DNA in both supernatant and cell pellet 
but DNA from the cell pellet produced better PCR results (Figure 11).  
 
 
Figure 11. PCR confirmation of HVT DNA. HVT DNA extraction was performed using the virus 
supernatant and the virus cell pellet separately. After DNA extraction, PCR was performed to confirm 
HVT DNA in the supernatant and in the cell pellet. The specific 94 bp PCR band, confirms HVT DNA in 
the both supernatant and cell pellet whereas HVT DNA in the cell pellet was much more than 
supernatant. 94 bp is the specific product size, s: PCR with the supernatant DNA as the template, p: 
PCR with the pellet DNA as the template, numbers 1-6 show different column washes to yield HVT 
DNA. Neg: negative control. 
 
3.2    Whole-ORFeome PCRs for H. pylori and HVT  
                              
H. pylori genome has 1437 open reading frames (ORFs) and HVT has 100 open reading 
frames (ORFs). PCR primers were designed for all of the ORFs as mentioned in section 2.7. 
After extracting of sequences from database and finding ORFs, primer design was performed 
for start and end of the ORFs. To have an expression construct ORF should be in frame, 
without stop codons and it should start with ATG. Forward primer starts at the ATG codon 
and reverse primer starts at the end of the ORFs. Each primer was considered to have 16-23 
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nucleotides, 50% GC content and 50°C Tm. Then binding specificity of each primer was 
checked by online blast tools. Because of different GC content at the beginning and at the 
end of a gene, primer designing with the similar criteria was not always possible and also in 
cell-free protein expression there were some difficulties in expression of ORFs more than 5 
kb, therefore with splitting a gene into two or three smaller sections it was possible to have 
better primer designs for PCR and also to have full protein expressions. Specific primers were 
flanked by two overhangs which then used for binding sites of second primers. In the second 
PCR regulatory sequences for transcription and translation and also His-Tag and V5-Tag 
sequences were added to ORFs. In the first PCR, specific primers amplified ORFs and in the 
second PCR, regulatory sequences were added to the ORFs (Figure 8). All of the PCRs were 
done on 96-well plates. The expression construct was generated by two successive PCRs and 
then checked for quality control by Gel Agarose Electrophoresis (Figure 12 and Figure 13). 
The PCRs were repeated to obtain the optimum result if they didn’t work or if they were 
evaporated especially at the corners of 96-well plates. After two successive PCRs, H. pylori 
ORFemoe and HVT ORFeome were generated. All of the PCR products were spotted using 
Nanoplotter 2.1 (GeSIM). Then the expression mix was added on the exact positions of the 
spotted PCR products. Afterwards in order to on-chip protein expression, the slides were 
placed in a humidified incubation chamber at 37°C, 50% humidity for 1 hour, and 
subsequently at 30°C, 50% humidity for 12 hours in a ventilated oven. Spotting was 
performed using the Nanoplotter 2.1 (GeSIM) and with a transfer file which has all the spot 
positions and commands. After producing protein microarrays, the existence of the 
expressed protein was checked by doing expression assay and after that the reactivity of 
these expressed proteins on the array with serum antibodies was checked by immunoassay. 
 
In the expression assay two antibodies with different fluorescent dyes were used to bind and 
detect the N-terminal His-Tag and C-terminal V5-Tag of the expressed proteins with red and 
green signals respectively. For this purpose, anti-His antibody (Alexa Fluor-647 conjugated, 
Qiagen) and anti-V5 antibody (Cy3 conjugated, Sigma) were applied during expression assay. 
In the immunoassay if there was specific antibody against proteins of H. pylori, the antibody 
would bind to the protein on the microarray and this binding was detected by using a 
secondary antibody (goat anti-human IgG, IgA, IgM Antibody, Jackson ImmunoResearch) 
which is conjugated to Alexa Flour-647 fluorescence dye. 
 
For expression assay signals from Alexa Fluor-647 and Cy3 fluorescent dyes were captured at 
the ratio of 635/532 nm in image acquisition. For immunoassay signal from Alexa Fluor-647 
fluorescent dye were captured at 635 nm wavelength in image acquisition. 
 
 
 
27 
 
 
 
Figure 12. Whole-ORFeome PCR for HVT genes. All of the HVT ORFs were amplified by two PCRs to 
generate expression constructs. All of the products were loaded on 1% agarose gel. 1 kb ladder was 
used to verify the correct length of PCR products. The number on each product represents the HVT 
gene symbol.  
 
 
 
Figure 13. Whole-ORFeome PCR for H. pylori genes. Example of H. pylori ORFs after two PCRs to 
generate expression constructs. All of the products were loaded on 1% agarose gel. 1 kb ladder was 
used to verify the correct length of PCR products. The sign on each product represents the H. pylori 
gene position. 
 
3.3    Positive controls for whole-proteome microarray 
 
To generate whole-proteome microarray and evaluation the expression assay and the 
immunoassay, negative and positive controls were produced by the same PCR plan that was 
used for all of the ORFs in this thesis. Positive PCRs contain known expression constructs 
which after incubation, the expressed protein was used as endogenous positive control. P18 
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antigen from Epstein-Barr-Virus (EBV) and F11 antigen from Poliovirus were used as positive 
controls. Negative PCRs which don’t have any expression construct were used as negative 
controls which also called Non Template Controls (NTC).  
 
3.3.1    EBV p18 PCR 
 
Epstein-Barr virus (EBV) is ubiquitous, and about 90% of adults throughout the world have 
IgG, IgM and IGA antibodies against p18 antigen. EBV p18 is also called Virus-Capsid-Antigen 
(VCA). ORF of EBV p18 was amplified by two successive PCRs to produce expression 
constructs.  
     
3.3.2.    Poliovirus F11 PCR 
 
Poliovirus F11 is a capsid antigen and ORF of Poliovirus F11 was amplified by two successive 
PCRs to produce expression constructs.  
 
 
3.4    Comparison of whole-proteome microarray on Epoxysilane (Epoxy)  
          and Ni-NTA (Ni) surfaces    
 
For whole-proteome microarray optimization, two different surfaces were used as the solid 
supports for expressed proteins. Spotting of antigens was performed on Ni and Epoxy slides 
and after incubation the obtained proteins were subjected to expression assay and 
immunoassay. The result was important to determine the solid surface which has the better 
result in case of protein expression and immunoassay. All of the procedures for Epoxy 
surface and Ni surface were performed at the same condition. The result was analyzed and 
calculated in GenePix pro 6.  
 
Figure 14. EBV p18, first and second PCRs. For 
generation expression constructs, ORF of EBV 
p18 was produced by two successive PCRs. The 
first PCR product is 530 bp and the second PCR 
product is 723 bp. The difference between two 
PCR product sizes is related to the length of the 
second PCR primers. 
Figure 15. Poliovirus F11, first and second PCRs. 
For generation expression construct, ORF of 
Poliovirus F11 was ordered and synthesized. Then 
two successive PCRs were performed to generate 
expression construct. The difference between 
two PCR product sizes is related to the length of 
the second PCR primers. 
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For comparison of two different surfaces, it was necessary to consider the background signal 
and standard deviation of the background. Thereby Signal to Noise Ratio (SNR) was used to 
compare the two different surfaces. The result was analyzed in terms of expression assay 
and immunoassay. 
 
3.4.1    Expression assay comparison of Epoxy and Ni surfaces 
 
After spotting and incubation, expression assay was performed for Epoxy slide and Ni slide 
and these two surfaces were subjected at wavelengths 635 nm (red signal) and 532 nm 
(green signal) which represent the His-Tag and V5-Tag of the expressed proteins 
respectively. In terms of quality and morphology for both the Ni and Epoxy surfaces, there 
was not detected smearing problem, rush on the slide and merged spots (Figure 16 a). Ni 
surface was observed to have a bigger spot size. Then the result was calculated to have a 
quantitative comparison. SNRs of 635 nm and 532 nm for each spot were calculated and 
compared. Higher SNR represents how much a signal of one spot, is higher than its 
background. Epoxy surface showed higher SNRs at both wavelengths 532 nm and 635 nm 
(Figure 16 b). In summary, Epoxy surface showed higher SNRs in compare of Ni surface 
however it is not significant. The higher SNR signal in Epoxy surface could be due to the 
smaller spot size. 
 
3.4.2    Immunoassay comparison of Epoxy and Ni surfaces 
 
Immunoassay was performed at the same situation for both Epoxy and Ni slides and the 
result was captured at wavelength 635 nm. Since in immunoassay not all of the spots were 
reactive to serum samples, positive controls which were reactive to serum samples were 
used to have a robust calculation. In terms of quality in Epoxy surface there was strong 
background which could mask the specific signal but in Ni slide, background signal was very 
low which led to significant positive signal. 
 
In terms of quantity, Signal to Noise Ratio (SNR) of Ni surface is much higher than Epoxy 
surface and also in Ni surface the difference between SNRs of Positives (Pos) and Negatives 
(Neg) is so much higher than Epoxy surface. 
 
In summary in Epoxy surface the specific signal could be masked by background. In Ni 
surface the specific signal was much more detectable because of low background. Based on 
this result, Ni surface was selected to be used for further experiments (Figure 17). 
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Figure 16. Qualitative and Quantitative comparisons of Epoxy and Ni slides in expression assay. 
After protein expression and immunostaining, Epoxy and Ni slides were scanned and the image was 
captured at the ratio of 635/532 nm. Regarding quality and morphology the spots on both Ni and 
Epoxy surfaces were resembled however spot size on Ni was larger (a). In quantitative comparison 
Epoxy and Ni slides were analyzed in terms of SNR. At both wavelengths 532 nm and 635 nm, Epoxy 
surface showed higher SNRs in compare of Ni surface (b). Red signal represented anti-His-Tag binding 
antibody at N-terminal of proteins. Green signal represented anti-V5-Tag binding antibody at C-
terminal of proteins and also green signal was a sign of protein full expression. Yellow signal 
represented combination of red and green signals. This image was taken by GenePix pro 6. *: P ≤ 
0.05, ns: P > 0.05.  
 
 
 
 
Figure 17. Qualitative and quantitative comparisons of Epoxy and Ni slides in immunoassay. In 
Epoxy surface, background signal was too high and it masked the positive signal. In Ni slide the 
background signal was low and the positive signal was completely significant. This result was 
captured at wavelength of 635 nm and 4x magnification by GenePix pro 6 (a). After calculation of 
both Ni and Epoxy surfaces, Ni slide showed a higher positive signal than Epoxy slide (b). *: P ≤ 0.05, 
***: P ≤ 0.001. 
 
a b 
a 
b 
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3.5    Optimization of E. coli lysate in Immunoassay 
 
One of the important things in immunoassay is reducing background to obtain optimum 
result. High background interferes with specific signal. Without reducing background, it is 
very hard to discriminate between positive and negative signals. Result showed that using E. 
coli lysate was very important in reducing background signals by collecting E. coli antibodies 
in serum. Serum sample should be incubated with E. coli lysate before using it on the slide. 
In another experiment different timepoints of incubation were tested and the result showed 
that two hours serum incubation with E. coli lysate provided the best result. 
 
 
 
 
 
Figure 18. Effect of E. coli lysate in immunoassay. The result of E. coli lysate incubation with serum 
samples is shown. Without E. coli lysate the difference between positive and negative signals was 
very low and positive signal was hardly detectable. This data showed using the E. coli lysate reduced 
background and nonspecific signal. P represented positive controls which are in duplicate and Neg 
represented negatives (a). To check the effect of incubation time of E. coli lysate, 5 different 
timepoints were tested and the results were compared. The result was analyzed based on SNR (b). 
This data showed two hours E. coli lysate incubation with serum sample before applying it on the 
slide, presented the highest signal. 
 
 
 
 
 
 
a 
b 
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3.6    Optimization of Betaine effect in whole-proteome microarray 
 
To prepare PCRs for spotting, Betaine 5 M was added to prevent evaporation and also it 
helps to increase transcription and translation by preventing secondary structure. 10% and 
20% of Betaine 5 M were used in total of spotting volume and the results were compared. 
When the Betaine amount was increased from 10% to 20%, morphology problems such as 
merged spots and rush on the slide were observed. 
 
 
 
 
3.7    Inconsistent spotting 
 
During optimization, inconsistent spotting was noticed. After expression assay the spots 
were only visible on some parts of the slide. This problem could be mechanical (spotter) or 
could be technical (during expression assay). To solve it, after spotting, exogenous protein 
fused to His-Tag was added on 4 places on the slide. Expression assay was performed and 
after staining the exogenous His-Tag protein was detected by antibody against His-Tag. This 
result showed that staining procedure was homogenous across the slide.  
 
 
Figure 20. Inconsistent spotting. Using His-Tag fused protein exogenously and staining it during 
expression assay represented homogenous staining across the slide. His-Tag proteins are shown in 
white squares. Image was captured at the ratio of 635/532 nm. 
 
 
Figure 19. Effect of Betaine amount. 10% 
Betaine 5 M is the optimum amount in 
PCRs for spotting. 20% Betaine 5 M in PCRs 
would result in merged spots and rush on 
the slide. Image was captured at the ratio 
of 635/532 nm. 
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3.8    Whole-proteome microarray of H. pylori  
 
All of the H. pylori ORFs were spotted on Ni slide to produce H. pylori protein microarray. 
After incubation the expressed proteins on the array were used for antibody staining to 
determine the protein expression. Two different conjugated antibodies with fluorescence 
labels were applied and the image was captured using ratio of 635/532 nm. Alexa Flour 
fluorescence dye reflects red and Cy3 fluorescence dye reflects green. One antibody is anti-
His-Tag which is labeled with Alexa Flour fluorescence dye. This antibody detects and binds 
to His-Tag of the expressed proteins. Another antibody is anti V5-Tag which is labeled with 
Cy3 fluorescence dye. This antibody detects and binds to V5-Tag of the expressed proteins 
on the array. The C-terminal V5-Tag of the expressed proteins was reflected as the green 
signal and green signal was the sign of protein full expression however the N-terminal His-
Tag of the expressed proteins was reflected as the red signal. The N-terminal His-Tag serves 
immobilization of the expressed proteins to Ni slide. 
 
H. pylori proteins were expressed on the array. H. pylori proteins with similar protein lengths 
spotted close to each other and protein lengths were increased from top to down of the 
array. EBV p18 and Poliovirus F11 were used for positive controls which they have known 
antigens to react to human serum samples whereas PCR without template was used for 
negative controls (Figure 21).  
 
3.9    Immunoassay of H. pylori 
 
Immunoassay was performed using healthy, chronic pancreatitis (CP) and pancreatic ductal 
adenocarcinoma (PDAC) serum samples. If there was specific antibody against proteins of H. 
pylori, the antibody would bind to the protein on the microarray and this binding was 
detected by using a secondary antibody which was conjugated to Alexa Flour fluorescence 
dye. Secondary antibody binds to Fragment crystallizable (Fc) region of IgA, IgG and IgM. 
Immunoassay was performed initially by using H. pylori positive and negative serum 
samples. The presence of antibodies and also their binding to the antigens on the microarray 
were proved by obtaining specific signal. Moreover, spotting of positive and negative 
controls on the array provided a valuable estimation of detecting positive candidates. 
Positive candidate should have a higher signal than negative controls. When a protein has a 
Median Fluorescence Intensity (MFI) larger than the cut off (Average of negative MFIs + 2.5 
SD of negatives) it is considered as a positive candidate (Figure 22). 
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Figure 22. Immunoassay of H. pylori 
negative and positive serum samples. All 
of 1437 H. pylori proteins were spotted on 
Ni surface and positive controls which 
were EBV p18 and Poliovirus F11 also 
spotted on the corners. Negative controls 
were spotted in the middle of positive 
controls. H. pylori negative and positive 
serum samples were used for 
immunoassay. By using H. pylori negative 
serum sample there were not any positive 
candidates but positive controls were 
detected as a sign of technical 
performance (a). Specific positive signals 
identified by using H. pylori positive 
serum sample (b). Pos represents positive 
controls. Neg represents negative 
controls. This image was captured at 
wavelength 635 nm. 
Figure 21. Expression assay result. 
H. pylori ORFeome was spotted on 
Ni surface and after incubation 
whole-proteome microarray was 
generated. Immunostaining was 
performed using two antibodies 
against His-Tag (red signal) and V5-
Tag (green signal). His-Tag is in the 
N-terminal of the newly expressed 
protein and serves to bind to Ni 
surface. V5-Tag is in the C-terminal 
of the newly expressed protein and  
it is a sign of full expression. Pos 
represents positive controls at four 
corners and Neg represents 
negative control on top and bottom 
of the slide. This image was 
captured at the ratio of 635/532 
nm. 
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3.9.1    Screening of H. pylori antigens in PDAC and non-PDAC serum pools 
 
After validation of immunoassay by using H. pylori negative and positive serum samples, 
serum samples of healthy, CP and PDAC were applied to the array. Whole-proteome 
microarrays comprised of 1437 H. pylori proteins were prepared and used to test with 
pooled serum samples to find the most promising candidates that might be relevant to PDAC 
condition. Some proteins were detected just in PDAC serum samples and could be relevant 
to PDAC pathogenesis and tumorigenesis. As H. pylori is a common infection in human being, 
it is possible to detect this bacterium in non-PDAC donors (healthy and CP) as well as PDAC 
patients, so I have also detected shared proteins between healthy, CP and PDAC (Figure 23). 
 
 
 
Figure 23. Example screening of positive candidates. 1437 H. pylori proteins were spotted on the 
array. Healthy, CP and PDAC serum samples were applied during immunoassay. H. pylori antigens 
were recognized based on the position on the array. Differential screening of H. pylori positive 
candidates showed some antigens were in common between healthy, CP and PDAC (blue squares), 
some antigens were detected just in healthy and CP (green squares) and some were specific for PDAC 
(yellow squares). To keep the clarity, just some of the antigens were labeled. 
 
Immunoassay was performed using pooled serum samples of CP and PDAC from Heidelberg 
University Clinic and healthy from Mannheim Blood Center. In this thesis this dataset is 
briefly called Heidelberg serum samples. 50 serum samples from healthy donors, 45 serum 
samples from CP donors and 50 from PDAC patients were included. 5 sera of each group 
were combined as one pool, resulting in a total of 10 healthy pools, 10 PDAC pools, and 9 CP 
pools. Figure 23 shows a descriptive image of whole-proteome microarrays incubated with 
PDAC serum samples which represents some of the detected antigens and Figure 24 shows 
the total detected antigens. In this screening, the prevalence of detected antigens in PDAC 
group and non-PDAC groups (healthy and CP) were estimated by the frequency of 
36 
 
seropositivity. A total of 46 proteins were detected in this experiment. The shortlisted 
candidates were ranked according to the frequency of seropositivity and the association with 
PDAC and non-PDAC (Figure 24). Antigen associations were measured and reported by Odds 
Ratio (OR) and 95% Confidence Interval (CI): 
 
OR=1 Exposure does not affect odds of outcome 
OR>1 Exposure associated with higher odds of outcome 
OR<1 Exposure associated with lower odds of outcome 
 
3.9.2    Screening of H. pylori antigens in individual PDAC and non-PDAC serum 
             samples                      
 
Using serum pools can be a fast way to find the reactive antigens but when pooling serum 
samples to have one serum pool with the same volume there are some considerations. 
Firstly, it is possible to dilute antibody level in a positive serum sample in other non-positive 
serum samples which can eliminate the positive signal (false negative). Secondly, combining 
different sera in one pool might have accumulative effect since different sera can recognize 
multiple epitopes of one antigen on the array. So some antigens can be detectable in pooled 
serum samples while they are not detectable in individual serum samples (false positive). 
Thirdly, combining different serum samples in one pool is reducing the size of dataset. For 
these reasons serum pools might not reflect all of the positive candidates and frequencies. 
For a better estimation it was important to apply a bigger dataset with individual serum 
samples. 
 
After screening of positive candidates in serum pools, to have a better estimation, individual 
serum samples of PDAC and non-PDAC (healthy and CP) were applied to the array. Whole-
proteome microarrays comprised of 1437 H. pylori proteins were prepared and used to test 
with individual serum samples to find the most promising candidates that might be relevant 
to PDAC condition. Immunoassay was performed using individual serum samples of healthy, 
CP and PDAC. 47 serum samples from PDAC patients and 38 serum samples from non-PDAC 
donors (19 serum samples from healthy and 19 serum samples from CP) were included. In 
this screening, the prevalence of the antigens in PDAC patients and non-PDAC donors 
(healthy and CP) were estimated by the frequency of seropositivity. A total of 62 proteins 
were detected in this experiment. The shortlisted candidates were ranked according to the 
frequency of seropositivity and the association with PDAC and non-PDAC serum samples. 
Antigen associations were measured and reported by Odds Ratio (OR) and 95% Confidence 
Interval (CI) (Figure 25). 
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Figure 24. Association of H. pylori positive candidates with PDAC serum pools. The frequency of 
positive candidates in PDAC and non-PDAC serum pools (a) and the positive candidates were ranked 
based on Odds Ratio and 95% CI (b). 
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 Figure 25. See next page.  
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Figure 25. Association of H. pylori positive candidates with PDAC serum samples. The frequency of 
positive candidates in individual PDAC and non-PDAC serum samples (a) and the ranking based on 
Odds Ratio and 95% CI (b), the frequency of positive candidates which were detected just in PDAC 
serum samples (c) and the ranking based on Odds Ratio and 95% CI (d). 
 
c 
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3.9.3 Comparison of H. pylori antigen screenings in pools and individual 
serum samples  
    
In the first screening of H. pylori antigens, 10 PDAC pools, 10 healthy pools and 9 CP pools 
were applied while in the second screening, 47 PDAC serum samples and 38 non-PDAC 
serum samples (19 healthy and 19 CP) were applied. Serum pools and individuals were from 
Heidelberg University Clinic (healthy samples were from Mannheim Blood Center). Antigen 
associations were measured and reported by Odds Ratio (OR) and 95% Confidence Interval 
(CI). In applying individual serum samples, the number of detected antigens is higher than 
using pools (62 antigens vs 46 antigens) (Figures 24 and 25). 33 antigens were in common 
between individuals and serum pools. Figure 26 a, b shows the frequency of the detected 
antigens between individuals and pools is not the same and Figure 26 c, d shows Odds Ratio 
(OR) of the antigens is not the same. Association patterns of most of the antigens were 
similar between individuals and pools while minority of the antigens such as HP0115 showed 
different patterns. Antigens were classified based on OR and +/+ means OR>1 and +/- means 
OR≤1 (Table 16). Figure 26 e, f shows 29 detected antigens in individual serum samples and 
they are not in pools, moreover these antigens only belong to PDAC serum samples but in 
low frequency and it might be due to higher number of PDAC serum samples. Figure 26 g, h 
shows 13 detected antigens just in serum pools and they belong to PDAC or non-PDAC serum 
pools. This data emphasized the role of individual serum samples for obtaining larger antigen 
list and better evaluation with exact frequency and Odds Ratio.  
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Figure 26. See next page. 
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Figure 26. Comparison of H. pylori antigen screenings in pools and individual serum samples.                  
The frequency of positive candidates between PDAC and non-PDAC individual samples (a) and in 
PDAC and non-PDAC serum pools (b). The positive candidates were ranked based on Odds Ratio and 
95% CI in individual serum samples (c) and in serum pools (d). The frequency of positive candidates 
which were detected just in individual PDAC serum samples (e), and the ranking based on Odds Ratio 
and 95% CI (f). The frequency of positive candidates which were detected just in PDAC or non-PDAC 
serum pools (g) and the ranking based on Odds Ratio and 95% CI (h). 
e 
f 
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Table 16. H. pylori antigens in Heidelberg individual serum samples and serum pools. 33 antigens 
were detected in both individual serum samples and serum pools and they were ranked based on 
association pattern and Odds Ratio average. +/+: OR>1 and +/-: OR≤1.   
 
 
 
Table 17. Top H. pylori positive candidates in Heidelberg individual serum samples and serum 
pools. Definition and function of top H. pylori positive candidates with the same association pattern.  
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3.9.4    Screening of H. pylori antigens in PDAC and non-PDAC serum pools with       
gastrointestinal conditions   
                   
In another screening, 19 serum pools with gastrointestinal disorders from Spanish National 
Cancer Research Centre (Madrid) which 11 serum pools were PDAC and 8 of them were non-
PDAC were applied to find H. pylori positive antigens (Table 18). Immunoassay was 
performed to find the antigens in PDAC and non-PDAC serum pools (Figure 27). A total of 59 
antigens were detected in this experiment and they were ranked based on frequency and 
Odds Ratio with 95% CI (Figure 28 a, b). 
 
 
 
 
 
Figure 27. Example of H. pylori immunoassay result and antigen detection in PDAC and non-PDAC 
serum pools with gastrointestinal conditions. Whole-ORFeome of H. pylori were spotted in 
microarray and after transcription and translation the expressed proteins were applied to 
Immunoassay by using PDAC and non-PDAC serum pools with gastrointestinal conditions. Green 
shows the specific antigen in non-PDAC pools, yellow shows the specific antigens in PDAC pools and 
blue shows the antigen in PDAC and non-PDAC pools. 
Table 18.  List of PDAC and non-PDAC serum 
pools from Madrid. PDAC and non-PDAC 
serum pools with gastrointestinal conditions. 
PDAC groups are in gray and non-PDAC 
groups are in white. UL: Ulcer disorder, H: 
Heartburn disorder, AR: Acid regurgitation 
disorder. Case: PDAC, cntr: non-PDAC. >2: 
gastrointestinal disorder was detected more 
than 2 years, <2: gastrointestinal disorder 
was detected less than 2 years. 
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Figure 28. Association of H. pylori positive candidates with PDAC serum pools in gastrointestinal 
conditions. The frequency of positive candidates in PDAC and non-PDAC serum pools (a) and the 
positive candidates were ranked based on Odds Ratio and 95% CI (b). 
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3.9.5    Comparison of H. pylori screenings in three serum datasets 
 
First screening was performed using PDAC and non-PDAC (CP and healthy) serum pools from 
Heidelberg University Clinic and Mannheim Blood Center and the second screening was 
performed using PDAC and non-PDAC (CP and healthy) individual serum samples from the 
same center. Third screening was performed using PDAC and non-PDAC serum pools with 
gastrointestinal conditions. Each screening has its advantage: in the first and second 
screening using CP and healthy groups as controls, could help to have a better screening of 
PDAC associated antigens. In the first screening, serum pools have presented a fast way of 
antigen screening (Figure 29 b, e) however pooling serum samples could have some 
considerations such as false negative antigens due to dilution effect of specific antibodies in 
pools and false positive due to accumulation effect of different antibodies for different 
epitopes of one antigen. To have a better estimation of antigen value, in the second 
screening, individual serum samples from the same center were applied instead of serum 
pools (Figure 29 a, d). In the third screening, PDAC and non-PDAC serum pools with 
gastrointestinal conditions from Madrid were applied to microarray. In this screening using 
serum pools with gastrointestinal disorders could help to subtract H. pylori gastrointestinal 
antigens from PDAC antigens (Figure 29 c, f). In the third screening by using PDAC and non-
PDAC serum pools with gastrointestinal conditions the Odds Ratios are lower in compare of 
the first and second screening. 
 
 In the next step three serum datasets were compared to find the H. pylori antigens. A total 
of 167 H. pylori antigens were detected while 36 H. pylori antigens were detected in three 
serum datasets. Figure 30 shows the frequency of the antigens in three serum datasets with 
the ranking based on Odds Ratio (OR) and the result was summarized in Table 19. Because of 
different serum sources, serum numbers and using pooled or individual serum samples in 
each experiment there was a small variation in antigen frequency and Odds Ratio in the 
three serum datasets. Some antigens such as HP0318 were detected in only two datasets but 
with different association patterns (OR>1 and OR≤1). Some antigens such as HP0599 and 
HP1477 were detected in two serum datasets with the same association pattern (OR>1). 
Some antigens such as HP1285 and HP0011 were detected in three datasets but only in two 
datasets they showed the same association pattern (OR>1). Finally, some antigens were 
detected in three datasets with the same association pattern: HP0874, HP01238, HP0601 
and HP0010 showed the same association pattern in three serum datasets (OR>1). Table 20 
shows description of top candidates in Heidelberg and Madrid serum datasets. 
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Figure 29. H. pylori antigen screenings by using three serum datasets. 1437 H. pylori antigens were 
spotted in microarray. The expressed proteins were applied to Immunoassay by using PDAC and non-
PDAC serum samples. The frequency of detected antigens in Heidelberg individual serum samples (a) 
in Heidelberg serum pools (b) and in Madrid serum pools (c). Detected antigens were ranked based 
on Odds Ratio and 95% CI in Heidelberg individual serum samples (d), in Heidelberg serum pools (e) 
and in Madrid serum pools (f). 
e d f 
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Figure 30. Comparison of H. pylori antigens in three serum datasets. After screening of H. pylori 
antigens by using serum datasets from Heidelberg and Madrid, 36 shared antigens were detected. 
The frequency of 36 antigens in PDAC and non-PDAC (CP and healthy) individual serum samples from 
Heidelberg (a), in PDAC and non-PDAC (CP and healthy) serum pools from Heidelberg (b) and in PDAC 
and non-PDAC serum pools with gastrointestinal conditions from Madrid (c). The antigens were 
ranked based on Odds Ratio and 95% CI in Heidelberg individual serum samples (d), in Heidelberg 
serum pools (e) and in Madrid serum pools (f).  
a 
b 
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Table 19. H. pylori antigens in three serum datasets. 36 antigens were detected in Heidelberg 
individual serum samples, Heidelberg serum pools and in Madrid serum pools. The result was ranked 
based on OR. Each group was separated based on association patterns in the three serum datasets. 
+/+: OR>1, +/-: OR≤1 and -/-: antigen was not detected. 
 
 
 
Table 20. Description of top H. pylori positive candidates. Definition and function of H. pylori 
positive candidates with triple +/+, with double +/+ and without +/-. +/+: OR>1, +/-: OR≤1 and -/-: 
antigen was not detected.   
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3.10    Whole-proteome microarray of turkey herpesvirus (HVT)  
 
HVT ORFeome were spotted on Ni slide to produce HVT protein microarray. After incubation, 
the expressed proteins on the array were used for immunostaining against His-Tag and V5-
Tag to determine the protein expression as mentioned in Table 13. EBV p18 antigen was 
used for positive control which it has known antigen to react to human serum samples 
whereas, Non Template Controls (NTC) were used for negative controls.  
 
 
 
3.11    Immunoassay of HVT 
 
3.11.1    Analysis of different blocking agents for immunoassay 
 
HVT immunoassay was performed with the same protocol as mentioned in Table 14, but the 
result was not sharp enough and there was not a big difference between positive candidates 
and other signals. So I decided to test different blocking agents to check which one ensured 
the highest sensitivity to find the optimum situation for HVT immunoassay. 11 different 
blocking buffers in total of 14 situations were tested (Table 21). Five blocking agents which 
have the highest positive signals and the lowest negative signals (Candor, SuperBlock, 
Nexterion Block E, NAP blocker and Milk powder) were selected. After obtaining these top 
five candidates, I tested again just these five blocking agents to find the best one. The result 
presented that Candor had the highest SNR Pos / SNR Neg in compare of other blocking 
agents (Figure 32). I used Candor as the blocking agent in HVT immunoassay. Candor (Candor 
Bioscience) and Milk powder (Bio-Rad) showed similar SNRs because they both contain 
segmented casein as the main agent in blocking buffer. 
 
Figure 31. Expression assay result of HVT 
microarray. HVT ORFeome were spotted on Ni 
slide and after incubation, immunostaining was 
performed using two antibodies against His-
Tag (red signal) and V5-Tag (green signal). P 
represents positive controls and Neg 
represents negative controls. 
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Table 21. List of blocking agents were analyzed in HVT immunoassay. 11 blocking agents in total of 
14 situations were tested and evaluated to find the most sensitive in immunoassay. 
 
 
Figure 32. Optimization result of HVT immunoassay. Top five blocking agents which were obtained 
from the primary experiment were confirmed to find the most optimum situation based on Signal to 
Noise Ratio (SNR). Candor and Milk powder showed the highest SNR. Candor was used in HVT 
immunoassay because of lower negative signal (data not shown). Water was used as controls instead 
of blocking buffers. 
 
3.11.2    Screening of HVT candidates in PDAC and non-PDAC serum pools 
 
Immunoassay was performed initially by using 50 serum samples of PDAC, 100 serum 
samples of non-PDAC serum samples (CP and healthy). Serum pools and individuals were 
from Heidelberg University Clinic (healthy samples are from Mannheim Blood Center). 5 sera 
of each respective group were combined as one pool, resulting in a total of 10 healthy pools, 
10 PDAC pools, and 10 CP pools. Candor was used as the blocking buffer and all of the 
settings and protocols were the same as explained in Table 14. When a protein showed 
Median Fluorescence Intensity (MFI) larger than the cut off (Average of negative MFIs + 2.5 
SD of negatives) it was considered as a positive candidate. Two PDAC pools showed positive 
signals whereas healthy and CP pools showed no positive signal. Then individual serum 
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samples of each positive pool were tested, and 3 individual serum samples were positive in 
each pooled serum (Figure 33). By using serum pools there were detected three positive 
candidates (HVT059, HVT062 and HVT079) which were ranked based on frequency and Odds 
Ratio with 95% CI (Figure 34). 
 
 
 
Figure 33. Immunoassay result of HVT microarray. HVT ORFeome were spotted on Ni slide and after 
protein expression healthy, CP and PDAC serum pools were applied during Immunoassay. HVT 
antigens were recognized based on the position on the array. HVT proteins were detected in two 
PDAC serum pools, and then these two pools were analyzed for individual serum samples. Three 
individual serum samples were positive in each serum pool.  
 
 
 
 
 
 
Figure 34. Association of HVT positive candidates with PDAC serum pools. The frequency of positive 
candidates: HVT059, HVT062 and HVT079 in PDAC serum pools (a) and the positive candidates were 
ranked based on Odds Ratio with 95% CI (b). 
a 
b 
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3.11.3    Screening of HVT antigens in PDAC and non-PDAC serum samples 
 
After immunoassay of serum pools, Individual serum samples were analyzed. 74 PDAC serum 
samples and 46 non-PDAC serum samples (24 CP serum samples and 22 healthy serum 
samples) were applied to HVT arrays. HVT positive candidates were detected in 21 (28%) 
PDAC serum samples whereas HVT positive candidates were not detected in non-PDAC (CP 
and healthy) serum samples. By using individual serum samples there were detected 25 HVT 
positive candidates which then ranked based on frequency and Odds Ratio with 95% CI. The 
detected candidates in pooled serum samples were also detected in individual serum 
samples (Figure 35). Top candidates were listed with gene description in Table 22. 
 
 
 
  
 
 Figure 35. Frequency and association of HVT positive candidates in PDAC serum samples. The 
frequency of positive candidates in PDAC serum samples (a) and the positive candidates were ranked 
based on Odds Ratio with 95% CI (b). 
 
a 
b 
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Table 22. Description of HVT positive candidates. HVT top candidates were classified based on 
detection in individual serum samples and pools. HVT059, HVT079 and HVT062 were detected in 
both Individuals and pools while HVT032, HVT017 and HVT022 were detected in individual serum 
samples. +/+: OR>1 and -/-: no detection.  
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4.    Discussion 
 
4.1    Cancer and infection 
 
Cancer is a complex disease with multiple causes. Among these causes, infection and its 
association to cancers have been studied for many years. Infection is the cause of nearly 20% 
of all cancers. Infectious agents such as the bacterium Helicobacter pylori (H. pylori) as the 
first known bacterial carcinogen and viruses from Herpesviridae family are involved in the 
pathogenesis of different cancers. Infection carries risks for disease development to drive 
carcinogenesis. Screenings of bacteria and virus antigens in cancer may uncover areas in the 
identification and optimizing cancer control strategies. 
 
Infection with H. pylori, which is a known carcinogen, may result in the development of 
adenocarcinoma. H. pylori has a strong adaptation to its natural habitat and they can modify 
their environment. H. pylori causes a mixed acute and chronic inflammatory reaction. 
Whereas infection typically does not show symptoms, it can lead to other diseases such as 
ulcer (gastric and duodenal) and gastric adenocarcinoma. 
 
Herpesviruses have applied number of immune evasion mechanisms. There are several 
carcinogenic mechanisms exploited by herpesviruses, including inhibiting apoptosis and 
tumor suppressors. Moreover, they are responsible for changing the microenvironment, 
promoting cellular migration, metastasis, angiogenesis, and also mutagenesis. Some of the 
members of Herpesviridae, such as Epstein-Barr virus (EBV) cause of lymphoma, 
cytomegalovirus (CMV) cause of brain tumors and Kaposi’s Sarcoma-associated 
herpesvirus (KSHV) are officially recognized as carcinogens.  
 
4.2    Whole-ORFeome for H. pylori and HVT 
 
Pure H. pylori genomic DNA was provided by ATCC. After checking the quality, it was used 
for PCR template. For HVT DNA there was not any pure DNA, so the virus was ordered with 
the infected cell. HVT DNA was extracted by using the supernatant and the cell pellet. Result 
showed that although the infected cells were harvested after cytopathic effect, HVT DNA 
was much more in the cell pellet rather than supernatant and this data could emphasize that 
HVT in viral culture is a cell associated virus and for preparing cell-free HVT, special 
treatment is needed (Zanella and Granelli 1974).  
 
H. pylori genome has 1437 open reading frames (ORFs) and HVT has 100 open reading 
frames (ORFs). PCR primers were designed for all of the ORFs to have whole-ORFeome. Each 
ORF sequence was obtained from database. To have an expression construct ORF should be 
in frame and without stop codons. Forward primer starts at ATG codon and reverse primer 
starts at end of the ORFs. Each primer was considered to have 16-23 nucleotides, 50% GC 
content and 50°C Tm. Then binding specificity of each primer was checked by online blast 
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tools. Because of different GC content at the beginning and end of a gene, primer designing 
with the similar criteria was not always possible and also in cell-free protein expression there 
were some difficulties in expression of long ORFs, therefore with splitting a gene into two or 
three sections it was possible to have better primer designs and to have full protein 
expressions. In this thesis as an example, HVT079 was divided into two sections and the first 
part of HVT079 showed positive signal. Specific primers were flanked by two overhangs 
which then used for binding sites of second primers. HVT specific primers were designed in 
our laboratory and H. pylori specific primers were designed by Heidelberg Unix Sequence 
Analysis Resources (HUSAR). Specific primers were designed and ordered to synthesize. The 
specific primers were used in first PCR were purified by chromatography. Second primer pair 
which was quite long was purified by high performance liquid chromatography (HPLC). 
 
First PCR was performed by using specific primers to amplify the ORFs. Primer Tm is very 
important in PCR optimization. There are different types of Tm(s) such as basic Tm, salt 
adjusted Tm and nearest neighbor Tm. Nearest neighbor Tm is very close to annealing 
temperature. Choosing nearest neighbor Tm prevents try and error to find the optimum 
annealing temperature. Using Betaine 5 M was helpful to enhance Taq polymerase activity 
and also it helps to open secondary structures. Since the specific primers were designed with 
the similar criteria the first PCR was performed with Taq DNA Polymerase (Qiagen). Second 
PCR was performed by using second primer pair for all of the PCRs and it seemed to be 
straightforward but in the second PCR, minority of reactions didn’t work and it was due to 
long product size and long primer size. By changing the polymerase from Qiagen Taq DNA 
Polymerase to Qiagen Long Range PCR kit, the optimum result was obtained. After two 
successive PCRs regulatory sequences for transcription, translation and protein tags were 
added to ORFs to generate expression constructs which then were used for whole-proteome 
microarray. 
 
4.3    Whole-proteome microarray for H. pylori and HVT 
 
After production of whole-ORFeome for H. pylori and HVT, they were spotted on slide. 45 µl 
of PCR product with 5 µl Betaine 5 M prepared for spotting. Then expression mix was added 
on top of each spot. For protein expression the whole array was incubated in a ventilated 
oven to produce whole-proteome microarray. This whole-proteome microarray was 
subjected to expression assay to check the protein expression and to immunoassay to check 
the seropositivity. Before doing expression assay and immunoassay there were some issues 
such as using Epoxy surface or Ni surface, importance of E. coli lysate and its optimum 
incubation time in immunoassay, using Betaine 5 M in spotting and inconsistence spotting.  
   
First of all, spotting was done on both Epoxy and Ni surfaces and each slide was subjected to 
expression assay and immunoassay to see the effect of the surface in protein expression and 
immunoassay. In the expression assay Epoxy and Ni surfaces showed acceptable similar 
quality without merged spots and rush on the slide and any other artifacts. Regarding spot 
size, Epoxy surface showed smaller and condensed spot in compare to Ni surface and it 
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might be the reason of higher SNR in Epoxy surface. In the immunoassay the Epoxy surface 
showed significantly lower SNR as a result of higher background. In the Ni surface, 
background was very low and foreground signal was much more visible.  
 
Testing immunoassay without using E. coli lysate showed huge background so even the 
positive controls could not be detected. Generally human sera contain antibody against E. 
coli and using E. coli lysate reduced background by absorbing these antibodies. Actually two 
hours serum incubation with E. coli lysate showed the best result. 
 
Each spotting solution was prepared by mixing of secondary PCR product with 10% Betaine 5 
M. Increasing Betaine 5 M from 10% to 20% resulted in rush on the slide and merged spots. 
Betaine 5 M helps to open secondary structures and also prevents evaporation. It seems 
increasing Betaine 5 M to 20% would decrease viscosity.   
 
Before doing the main experiments and during testing a few PCR products, inconsistent 
spotting was noticed. Same protein expressions should be visible across the slide but it was 
visible only on upper part of the slide. Adding exogenous protein fused to His-Tag across the 
slide showed this problem arose from spotting and not from expression assay. Spotter 
optimization solved this problem. 
 
H. pylori and HVT whole-ORFeome were spotted on Ni surface and after incubation whole-
proteome microarray were produced. This microarray was checked for protein expression 
and immunoassay respectively. EBV p18 and Poliovirus F11 antigens were used as 
endogenous positive controls and their expression and detection showed technical 
performance.  
 
4.4   Identification and screening of PDAC associated antigens  
 
Each person shows specific antibodies for infection agents and disease conditions. 
Antibodies detect and bind to pathogens and toxins to facilitate phagocytosis of foreign 
substances by phagocytic cells. After phagocytosis the antigens are digested to present part 
of the antigens as epitopes to T cells. Epitope presentation is done by MHC class I to 
cytotoxic T cells for viruses and MHC class II to helper T cells for bacteria. Because of 
different genetic background, type of infection and immune responses over time, antibody 
patterns could be different between people. As a result, it is possible that special antibody 
patterns which are associated with disease conditions could be detectable for diagnosis. 
Using H. pylori positive and negative serum samples showed specific signals in H. pylori 
positive serum sample whereas there were not specific signals in H. pylori negative serum 
sample. While a protein showed MFI larger than the cut off (Average of negative MFIs + 2.5 
SD of negatives) it was considered as a positive candidate. This data showed that serum 
antibodies of patients can detect and bind to specific H. pylori antigens among many other 
antigens on the microarray. During HVT experiment also it was noticed that only some 
serum samples showed antibody against HVT proteins on the microarray. In conclusion due 
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to specific antibody patterns and seropositivity I was able to detect and screen H. pylori and 
HVT antigens based on frequency, Odds Ratio and association patterns to PDAC. In this work 
three screenings were performed for H. pylori and two screenings were performed for HVT. 
 
4.5    H. pylori positive candidate screening 
 
Firstly, immunoassay was performed using pooled serum samples of CP and PDAC from 
Heidelberg University Clinic and healthy from Mannheim Blood Center. In this thesis this 
dataset is briefly called Heidelberg. 50 serum samples from healthy donors, 45 serum 
samples from CP donors and 50 from PDAC patients were included. 5 sera of each group 
were combined as one pool, resulting in a total of 10 healthy pools, 10 PDAC pools, and 9 CP 
pools. In this screening, the prevalence of detected antigens in PDAC groups and non-PDAC 
groups (healthy and CP) were estimated by the frequency of seropositivity. The shortlisted 
candidates were ranked according to the frequency of seropositivity and the association with 
PDAC and non-PDAC. A total of 46 proteins were detected in this experiment and five of 
them showed higher association to PDAC: HP0231, HP011, HP0175, HP1125 and HP0599. 
“HP0231 is a dimeric oxidoreductase that functions in an oxidizing disulfide bonds pathway 
of H. pylori. Many H. pylori virulence factors are stabilized by the formation of disulfide 
bonds and the lack of H. pylori HP0231 damaged CagA translocation into gastric epithelial 
cells and reduced VacA vacuolation” (Zhong et al. 2016). HP011 is a co-chaperonin in protein 
folding. “HP0175 induces apoptosis of gastric epithelial cells” (Basak et al. 2005). HP1125 is 
an outer membrane protein (omp18) which altered IFN-gamma to avoid immune response 
(Shan et al. 2015). HP0599 is a hemolysin secretion protein and it is important in H. pylori 
chemotaxis (Scott et al. 2007). 
 
Secondly, using serum pools can be a fast way to find the reactive antigens but when pooling 
serum samples to have one serum pool with the same volume there are some 
considerations. It is possible to dilute antibody level of a positive serum sample in other non-
positive serum samples which can eliminate the positive signal (false negative). Combining 
different sera in one pool might have accumulative effect since different sera might 
recognize and bind to multiple epitopes of an antigen on the array. So some antigens can be 
detectable in pools while they are not detectable in individual serum samples (false positive). 
Moreover, in combining different serum samples in one pool we are reducing the size of 
dataset. For these reasons serum pools might not reflect all of the positive candidates and 
the frequencies. For a better estimation I needed to apply a bigger dataset with individual 
serum samples. So this time individual serum samples from Heidelberg were applied to 
microarray. In this section 47 PDAC serum samples and 38 non-PDAC serum samples (19 
healthy and 19 CP) were applied. A total of 62 proteins were detected in this experiment and 
six antigens showed higher association to PDAC: HP0874, HP0599, HP0175, HP0231, 
HP01285 and HP0011. Four antigens of six antigens were already mentioned in Heidelberg 
pools and here another two antigens are mentioned: HP0874 and HP01285; HP0874 (KapA) 
is responsible for H. pylori hydrogen peroxide resistance (Harris et al. 2002). HP1285 is a 
hypothetical protein.  
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Thirdly, in another experiment 19 serum pools with gastrointestinal disorders from Spanish 
National Cancer Research Centre (Madrid) including 11 PDAC and 8 non-PDAC serum pools 
were applied to find H. pylori positive antigens. Immunoassay was performed to find the 
antigens in PDAC and non-PDAC serum pools. In total of 59 antigens were detected in this 
experiment and top six of detected antigens are: HP0010, HP1117, HP0874, HP0601, HP1564 
and HP1492. HP0010 is a chaperone. HP1117 is a hypothetical protein and assumed to be a 
Sel1 repeat-containing protein. HP0601 is flagellin and important in H. pylori colonization. 
HP1564 is ABC transporter and HP1492 is a hypothetical protein which is suggested for H. 
pylori oxidative stress resistance (Benoit et al. 2018). In this screening by using PDAC and non-
PDAC serum pools with gastrointestinal conditions the Odds Ratios are lower in compare of 
the first and second screenings and it could be due to existence of the same gastrointestinal 
conditions in PDAC and non-PDAC groups. 
 
4.6    Comparison of H. pylori screening results in three serum datasets 
 
First screening was performed by using PDAC and non-PDAC (CP and healthy) serum pools 
from Heidelberg and the second screening was performed by using PDAC and non-PDAC (CP 
and healthy) individual serum samples from the same center. Third screening was performed 
by using PDAC and non-PDAC serum pools with gastrointestinal conditions from Madrid. 
Each screening has its advantage: in the first and second screenings using CP and healthy 
groups as controls could help us to have a better screening of PDAC associated antigens. In 
the first screening, serum pools have presented a fast way of antigen screening however 
pooling serum samples could have some considerations such as false negative antigens due 
to dilution effect of specific antibodies and false positive due to accumulative effect of 
different sera for multiple epitopes of one antigen. So some antigens could be detectable 
only in pooled serum samples or in individual serum samples. To have a better estimation of 
antigen value, in the second screening individual serum samples from the same center were 
applied instead of serum pools. In the third screening PDAC and non-PDAC serum pools with 
gastrointestinal conditions from Madrid were applied to microarray. In this screening using 
serum pools with gastrointestinal disorders can help us to subtract H. pylori gastrointestinal 
antigens from PDAC antigens.  
 
Comparison result of two serum datasets from Heidelberg (pools and individual serum 
samples) showed that in applying individual serum samples the number of detected antigens 
is higher than using pools (62 antigens vs 46 antigens). 33 antigens were in common 
between individuals and serum pools. Odds Ratio (OR) of the antigens was not exactly the 
same but association patterns of most of the antigens were similar between individuals and 
pools while minority of the antigens such as HP0115 showed different patterns (OR>1 and 
OR≤1). 26 antigens showed the same association pattern and 20 of them showed positive 
associations to PDAC in pools and individuals (OR>1). This data emphasized the importance 
of individual serum samples for obtaining a larger antigen list and a better evaluation with 
exact frequency and Odds Ratio however using serum pools was a fast way to obtain top 
candidates. In the next step three serum datasets were compared to find the shared H. pylori 
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antigens. In total of 167 H. pylori detected antigens, 36 H. pylori antigens were detected in 
common in three serum datasets. Because of different serum sources, serum numbers and 
using pooled and individual serum samples there was expected some variations in antigen 
frequency and Odds Ratio. Some antigens such as HP0318 were detected in only two 
datasets but with different association patterns to PDAC (OR>1 and OR≤1). Some antigens 
such as HP0599 and HP1477 were detected in two serum datasets with the same association 
pattern (OR>1). Some antigens such as HP1285 and HP0011 were detected in three datasets 
but only in two datasets they showed the same association pattern to PDAC (OR>1). Finally, 
four antigens were detected in three datasets with the same association pattern to PDAC 
(OR>1): HP0874, HP01238, HP0601 and HP0010. Table 20 shows description of top candidate 
in Heidelberg and Madrid serum datasets. HP0874 (KapA) is responsible for H. pylori 
hydrogen peroxide resistance (Harris et al. 2002). HP1238 is a formamidase which involves in 
nitrogen and carbon metabolism. HP0601 is flagellin and important in H. pylori colonization. 
HP0010 is a GroEL chaperone. 
 
4.7    HVT positive candidate screening 
 
Immunoassay was performed initially by using CP and PDAC serum samples from Heidelberg 
University Clinic and healthy serum samples from Mannheim Blood Center. In this thesis this 
dataset was briefly called Heidelberg serum samples. 50 serum samples of PDAC, 100 serum 
samples of non-PDAC serum samples (CP and healthy) were applied. 5 sera of each 
respective group were combined as one pool, resulting in a total of 10 healthy pools, 10 
PDAC pools, and 10 CP pools. The first immunoassay by using Superblock as blocking buffer 
didn’t show very good signal. Then 11 blocking buffers were tested to find the most sensitive 
one and Candor was used as the blocking buffer. Two PDAC pools showed positive signals 
whereas healthy and CP pools showed no positive signal. By using serum pools there were 
detected three positive candidates (HVT059, HVT062 and HVT079) in PDAC serum pools. 
After immunoassay of serum pools, Individual serum samples were analyzed. 74 PDAC serum 
samples and 46 non-PDAC serum samples (24 CP serum samples and 22 healthy serum 
samples) were applied to HVT array. HVT positive candidates were detected in 21 (28%) 
PDAC serum samples whereas HVT positive candidates were not detected in non-PDAC (CP 
and healthy) serum samples. By using individual serum samples there were detected 25 HVT 
positive candidates. The detected candidates in pooled serum samples (HVT059, HVT062 
and HVT079) were also detected in individual serum samples. HVT059 is defined as 
envelope/tegument protein, HVT079 is defined as apoptosis inhibitor Bcl-2 which regulates 
cell death and HVT062 is envelope glycoprotein K. HVT032 and HVT022 are involved in viral 
DNA packaging. 
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5.    Conclusion 
 
Cell-free protein microarray is a strong and pioneering technology for the detection of 
positive candidates, novel biomarkers and protein-antibody reactivities. Protein purification 
is expensive and time-consuming and could destroy the protein structure and function. Cell-
free protein microarray technology avoids protein purifications by replacing expression in 
situ with an in vitro transcription-translation. This technology allows doing high-throughput 
approaches for the analysis of the proteome at large scales (Merbl and Kirschner 2010). In 
comparison to other proteomics methods, cell-free protein microarray avoids the necessity 
of purification a sample into small parts and therefore complex samples can be immediately 
applied for research (Hanash 2003). 
 
In cell-free protein microarray, the expressed proteins are produced from a special template 
with transcription and translation elements on the surface and the expressed protein is 
captured by affinity reagents. In our method the DNA template was an expression construct 
with His-Tag and V5-Tag which was flanked by regulatory sequences, made by two 
successive PCRs and after in vitro transcription-translation, nascent protein bound to the Ni 
surface by His-Tag. In this study after technique establishment, H. pylori whole-proteome 
microarray and HVT whole-proteome microarray were produced from H. pylori ORFeome 
and HVT ORFeome. Cell-free protein microarray allows performing high-throughput 
approaches for the analysis of the proteome at large scales for diagnostic purposes (Díez et 
al. 2015).  
 
In this study firstly, whole-ORFeome and whole-proteome were produced and after checking 
the protein expression on the array, immunoassay was performed by using PDAC and non-
PDAC serum samples. After screening of positive candidates which should have signal larger 
than the cut off (Average of negative MFIs + 2.5 SD of negatives), the result was screened 
based on frequency in each PDAC and non-PDAC groups and also the positive candidates 
were ranked based on Odds Ratio to see the association patterns to PDAC and non-PDAC 
groups. Moreover, some serum samples were tested randomly to check the reproducibility. 
In this study for H. pylori screening three serum datasets were used. Result for each dataset 
could be valuable for diagnostic purposes but a strict comparison of results was performed 
to detect positive candidates in three datasets. In H. pylori screenings, among 167 positive 
candidates four of them (HP0874, HP0010, HP0601 and HP1238) were detected to be 
associated with PDAC condition in three datasets (triple +/+) which might have diagnostic 
value. In comparison of three serum datasets the difference between detected antigens was 
expected. Using individual serum samples and pooled serum samples could bring different 
data. In individual serum samples there were detected more antigens with different 
frequencies but association patterns of most of the antigens were similar to pooled serum 
samples. Comparison of Heidelberg and Madrid serum samples showed less similarity 
however finding 36 H. pylori antigens between Heidelberg and Madrid was promising. This 
difference between Heidelberg and Madrid is firstly because of different ethnicity and 
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different genetic background and secondly is due to the special gastrointestinal conditions in 
Madrid serum samples. 
 
In this study for HVT screening two serum datasets were used. Result for each dataset could 
be valuable for diagnostic purposes but comparison of results was performed to detect 
shared positive candidates in two datasets. In HVT screenings three antigens were detected 
(HVT059, HVT062 and HVT079) to be associated with PDAC condition in pooled and 
individual serum samples.  
 
Cell-free protein microarray has shown numerous benefits but it is possible that cell-free 
protein microarray is not able to detect all of the reactive antigens. There are several 
reasons for missing of some reactive antigens. Firstly, it can be related to the protein 
expression on the array. Antibody binding to antigen on the array is prevented if the protein 
is not fully expressed. As a result, antibody could not bind to antigen. Secondly, using strict 
cut off to screen positive candidates might result in missing of some antigens which are 
reactive but the signal is under cut off. Thirdly protein folding can mask the epitope, so 
antibody could not access to epitope and also adding protein tags could also mask the 
epitope. Lastly, using pooled serum samples leads to some considerations such as antibody 
dilution in a pool which results in negative signal.  
 
In this study for H. pylori and HVT three and two list of promising antigens were produced 
which can be valuable for further PDAC diagnostic purposes. Moreover, strict antigen 
comparison was performed to find the antigens which are associated to PDAC in all of the 
used serum datasets.   
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Summary 
Background 
Infection is the cause of nearly 20% of all cancers. Infectious agents such as the bacterium 
Helicobacter pylori (H. pylori) as the first known bacterial carcinogen and viruses from 
Herpesviridae family are involved in the pathogenesis of different cancers. Screening for 
antibodies against bacterial and viral antigens in cancer patients may therefore uncover 
potential markers and targets for optimized cancer control strategies. To these ends, I 
studied the antibody composition in the peripheral blood of patients with pancreatic ductal 
adenocarcinoma (PDAC) and appropriate non-cancer donors as controls. 
Methods 
All 1437 open reading frames (ORFs) of H. pylori and the 100 ORFs of Turkey herpesvirus 
(HVT) were produced by two successive PCRs and spotted on nickel-coated glass surfaces. By 
in vitro transcription-translation, whole-proteome microarrays were produced for H. pylori 
and HVT. Immunoassays were performed with PDAC and non-PDAC serum samples to detect 
antibody binding patterns and to differentiate between PDAC and non-PDAC groups. For 
presenting the association pattern of each detected antigen with PDAC, the result was 
calculated as Odds Ratio (OR) with 95% Confidence Interval (CI). Also, functional annotations 
were performed. 
Results 
At first, the H. pylori proteome was screened using serum pools of 10 PDAC, 10 healthy and 
9 CP (chronic pancreatitis). A total of 46 proteins were detected, of which 29 showed 
association to PDAC (OR>1). After screening for candidates in the serum pools, individual 
serum samples of PDAC and non-PDAC (healthy and CP) were applied to the microarray. In 
total, 47 PDAC and 38 non-PDAC samples (19 healthy and 19 CP) were analyzed. A total of 
62 proteins were detected. Most of them showed association to PDAC (OR>1); 33 antigens 
had also been found in the pool experiments, such as HP0874, HP0599 and HP0175. In 
further experiments, 11 PDAC and 8 non-PDAC serum pools with gastrointestinal conditions 
were applied to find H. pylori positive antigens. In total, 59 antigens were detected in this 
experiment of which 29 showed association to PDAC (OR>1).  
 
The HVT proteome was firstly screened using serum pools (10 PDAC, 10 healthy and 10 CP). 
In this step, three antigens were detected in PDAC pools. Subsequently, screening was 
performed using individual samples. Altogether, 74 PDAC and 46 non-PDAC serum samples 
(24 CP patients and 22 healthy donors) were applied to the HVT microarray. In total, 25 HVT 
candidates were identified including the antigens which were detected in the pools: 
HVT079, HVT059 and HVT062. 
Conclusions 
H. pylori and HVT screenings were performed to find antigens which are associated with the 
occurrence of PDAC using serum pools and individual serum samples. Each screening 
produced a candidate list, which is a valuable resource for diagnostic purposes. Among the 
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167 H. pylori detected antigens, four antigens were detected in all three datasets with strong 
association to PDAC: HP0874, HP0010, HP0601 and HP01238. Among the 25 HVT proteins 
that were detected, three were detected commonly: HVT079, HVT059 and HVT062. These 
results could help PDAC diagnostics and provides targets for interfering with PDAC 
development and progression. 
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Zusammenfassung 
Hintergrund 
Infektion ist die Ursache von fast 20% aller Krebsarten. Infektionserreger wie das Bakterium 
Helicobacter pylori (H. pylori) als erstes bekanntes bakterielles Karzinogen und Viren aus der 
Familie der Herpesviridae sind an der Pathogenese verschiedener Krebsarten beteiligt. Das 
Screening auf Antikörper gegen bakterielle und virale Antigene in Krebspatienten kann daher 
potenzielle Marker und Ziele für optimierte Strategien zur Krebsbekämpfung aufdecken. Zu 
diesem Zweck untersuchte ich die Antikörper-Zusammensetzung im peripheren Blut von 
Patienten mit duktalem Adenokarzinom des Pankreas (PDAC) und geeigneten Nicht-Krebs-
Spendern als Kontrollen. 
Methoden 
Alle 1437 offenen Leserahmen (ORFs) von H. pylori und die 100 ORFs des Truthahn 
Herpesvirus (HVT) wurden durch zwei aufeinanderfolgende PCRs hergestellt und auf 
nickelbeschichteten Glasoberflächen aufgebracht. Durch in vitro Transkription/Translation 
wurden Mikroarrays des gesamten Proteoms von sowohl H. pylori als auch HVT hergestellt. 
Immunoassays wurden mit PDAC- und Nicht-PDAC-Serumproben durchgeführt, um 
Antikörperbindungsmuster nachzuweisen und zwischen PDAC- und Nicht-PDAC-Gruppen zu 
unterscheiden. Zur Darstellung der Assoziation jedes nachgewiesenen Antigens mit PDAC 
wurde das Ergebnis als „Odds-Ratio“ (OR) mit 95% Konfidenzintervall (CI) berechnet. Auch 
funktionale Annotationen wurden durchgeführt. 
Ergebnisse 
Zunächst wurde das H. pylori-Proteom mit Serumgemischen aus Blutproben von 10 PDAC-
Patienten, 10 gesunden Personen und 9 Patienten mit chronischer Pankreatitis (CP) 
untersucht. Insgesamt wurden 46 Proteine nachgewiesen, von denen 29 eine Assoziation mit 
PDAC zeigten (OR> 1). Nach der Analyse der Serumgemische wurden einzelne Serumproben 
von PDAC und Nicht-PDAC (gesund und CP) auf den Microarrays untersucht. Insgesamt 
wurden 47 PDAC- und 38 Nicht-PDAC-Proben (19 gesunde und 19 CP) analysiert. Insgesamt 
wurden 62 Proteine nachgewiesen. Die meisten von ihnen zeigten eine Assoziation mit PDAC 
(OR> 1); davon waren 33 Antigene auch in den Analysen mit Probengemischen gefunden 
worden, wie beispielsweise HP0874, HP0599 und HP0175. In weiteren Experimenten wurden 
11 PDAC- und 8 Nicht-PDAC-Serumgemische untersucht, für die eine genaue Annotation des 
gastrointestinalen Gesundheitszustands vorlag, um wiederum H. pylori-Antigene zu finden. 
Insgesamt wurden in diesem Experiment 59 Antigene nachgewiesen, von denen 29 eine 
Assoziation mit PDAC zeigten (OR> 1).  
 
Die HVT-Proteine wurden zunächst unter Verwendung von Serumgemischen (10 PDAC, 10 
gesunde und 10 CP) analysiert. In diesem Schritt wurden in den PDAC Serumgemischen 
Antikörper gegen drei spezifische Antigene nachgewiesen. Anschließend wurde ein 
„Screening“ mit Einzelproben durchgeführt. Insgesamt wurden 74 PDAC- und 46 Nicht-PDAC-
Serumproben (24 CP-Patienten und 22 gesunde Spender) auf den HVT-Microarrays 
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untersucht. Dabei wurden 25 HVT-Proteine identifiziert, einschließlich der Antigene, die 
bereits in den Gemischen nachgewiesen wurden: HVT079, HVT059 und HVT062. 
Schlussfolgerungen 
Analysen von Serumproben auf Darstellungen des Proteoms von H. pylori und HVT wurden 
durchgeführt, um Antigene zu finden, die mit dem Auftreten von PDAC assoziiert sind, wobei 
Serumpools und einzelne Serumproben verwendet wurden. Aus jedem „Screening“ wurde 
eine Kandidatenliste erstellt, die eine wertvolle Ressource für diagnostische Zwecke darstellt. 
Unter den 167 H. pylori-Proteinen wurden vier Antigene in allen drei Datensätzen mit starker 
Assoziation zu PDAC nachgewiesen: HP0874, HP0010, HP0601 und HP01238. Unter den 25 
nachgewiesenen HVT-Proteinen wurden folgende drei häufig nachgewiesen: HVT079, 
HVT059 und HVT062. Diese Ergebnisse könnten die PDAC-Diagnose unterstützen und 
Zielmoleküle für eine mögliche Behandlung der PDAC Entwicklung und Progression liefern. 
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Appendix 1: Result of H. pylori screening with Heidelberg serum pools 
 
Gene 
symbol 
 
 
10 PDAC 9 
CP 
10 
healthy 
19 
non-
PDAC 
PDAC 
% 
non-
PDAC 
% 
Odds 
Ratio 
95% CI 
HP0231 3 0 0 0 30% 0% 18.2 0.8360 to 396.2356 
HP0011 4 0 1 1 40% 5% 12.0 1.1126 to 129.4217 
HP0175 2 0 0 0 20% 0% 11.5 0.4958 to 265.4033 
HP1125 2 0 0 0 20% 0% 11.5 0.4958 to 265.4033 
HP0599 2 0 0 0 20% 0% 11.5 0.4958 to 265.4033 
HP0010 3 0 1 1 30% 5% 7.7 0.6820 to 87.2557 
HP1350 3 0 1 1 30% 5% 7.7 0.6820 to 87.2557 
HP0202 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP0444 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP1250 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP0686 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP0601 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP0294 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP0115 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP0079 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP1434 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP1477 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP1285 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP0874 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP1071 1 0 0 0 10% 0% 6.2 0.2287 to 165.8376 
HP0243 4 1 1 2 40% 10% 5.7 0.8177 to 39.2689 
HP1341 7 5 5 10 70% 50% 2.1 0.4136 to 10.6637 
HP1038 2 0 2 2 20% 10% 2.1 0.2519 to 17.9273 
HP1238 1 0 1 1 10% 5% 2.0 0.1117 to 35.8086 
HP0073 1 0 1 1 10% 5% 2.0 0.1117 to 35.8086 
HP1563 1 0 1 1 10% 5% 2.0 0.1117 to 35.8086 
HP0547 1 0 1 1 10% 5% 2.0 0.1117 to 35.8086 
HP0385 1 0 1 1 10% 5% 2.0 0.1117 to 35.8086 
HP1199 1 1 1 2 10% 10% 1.1 0.0835 to 13.5172 
HP0371 3 2 4 6 30% 31% 0.93 0.1761 to 4.8976 
HP0582 2 2 2 4 20% 21% 0.9 0.1399 to 6.2804 
HP1453 2 2 2 4 20% 21% 0.9 0.1399 to 6.2804 
HP0638 6 6 7 13 60% 68% 0.7 0.1408 to 3.4038 
HP0185 0 1 0 1 0% 5% 0.6 0.0219 to 15.7497 
HP0961 0 1 0 1 0% 5% 0.6 0.0219 to 15.7497 
HP0476 0 1 0 1 0% 5% 0.6 0.0219 to 15.7497 
HP1542 0 1 0 1 0% 5% 0.6 0.0219 to 15.7497 
HP0077 0 1 0 1 0% 5% 0.6 0.0219 to 15.7497 
HP0990 0 0 1 1 0% 5% 0.6 0.0219 to 15.7497 
HP1124 0 0 1 1 0% 5% 0.6 0.0219 to 15.7497 
HP1442 0 0 1 1 0% 5% 0.6 0.0219 to 15.7497 
HP0251 0 0 1 1 0% 5% 0.6 0.0219 to 15.7497 
HP0279 0 0 1 1 0% 5% 0.6 0.0219 to 15.7497 
HP0542 0 0 1 1 0% 5% 0.6 0.0219 to 15.7497 
HP1389 0 0 1 1 0% 5% 0.6 0.0219 to 15.7497 
HP1129 0 0 1 1 0% 5% 0.6 0.0219 to 15.7497 
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Appendix 2: Result of H. pylori screening with Heidelberg serum individuals
 
Gene 
symbol 
47 
PDAC 
19 
CP 
19 
healthy 
38 non-
PDAC 
PDAC 
% 
non-
PDAC % 
Odds 
Ratio 
95% CI 
HP0874 8 0 0 0 17% 0% 16.6 0.9241 to 297.1165 
HP0599 7 0 0 0 15% 0% 14.3 0.7873 to 258.2594 
HP0175 6 0 0 0 12% 0% 12 0.6572 to 221.3291 
HP0231 5 0 0 0 10% 0% 10 0.5333 to 186.1999 
HP1285 5 0 0 0 10% 0% 10 0.5333 to 186.1999 
HP0011 7 1 0 1 15% 3% 6.5 0.7599 to 55.1711 
HP1563 2 0 0 0 4% 0% 4.2 0.1971 to 90.8297 
HP0028 2 0 0 0 4% 0% 4.2 0.1971 to 90.8297 
HP0900 2 0 0 0 4% 0% 4.2 0.1971 to 90.8297 
HP0522 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0708 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0449 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0141 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP1017 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0318 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0331 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP1564 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP1105 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0399 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0178 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP1162 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0325 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0393 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0550 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0320 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP1538 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0485 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0256 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP1175 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0059 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP1544 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0099 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP1006 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0675 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0054 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP0092 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP1125 1 0 0 0 2% 0% 2.5 0.0984 to 62.7308 
HP1038 3 0 1 1 6% 3% 2.5 0.0984 to 62.7308 
HP0202 1 0 0 0 2% 0% 2.4 0.0938 to 59.8236 
HP1250 1 0 0 0 2% 0% 2.4 0.0938 to 59.8236 
HP0294 1 0 0 0 2% 0% 2.4 0.0938 to 59.8236 
HP1434 1 0 0 0 2% 0% 2.4 0.0938 to 59.8236 
HP0243 1 0 0 0 2% 0% 2.4 0.0938 to 59.8236 
HP1238 1 0 0 0 2% 0% 2.4 0.0938 to 59.8236 
HP0601 2 0 1 1 4% 3% 1.6 0.1365 to 17.9542 
HP1199 2 0 1 1 4% 3% 1.6 0.1365 to 17.9542 
HP0010 3 0 2 2 6% 5% 1.2 0.1944 to 7.7481 
74 
 
HP1350 3 0 2 2 6% 5% 1.2 0.1944 to 7.7481 
HP0385 3 0 2 2 6% 5% 1.2 0.1944 to 7.7481 
HP0542 3 1 1 2 6% 5% 1.2 0.1944 to 7.7481 
HP0638 4 1 2 3 8% 8% 1.1 0.2276 to 5.1753 
HP1453 5 1 3 4 11% 10% 1 0.2519 to 4.0642 
HP1341 8 4 3 7 17% 18% 0.9 0.2968 to 2.7805 
HP0079 1 0 1 1 2% 3% 0.8 0.0486 to 13.2995 
HP0077 1 1 0 1 2% 3% 0.8 0.0486 to 13.2995 
HP1124 2 0 2 2 4% 5% 0.8 0.1074 to 5.9611 
HP0371 4 2 3 5 9% 13% 0.6 0.1528 to 2.4670 
HP0547 2 0 3 3 4% 8% 0.5 0.0821 to 3.2745 
HP0582 7 4 7 11 15% 29% 0.4 0.1479 to 1.2473 
HP0073 0 0 1 1 0% 3% 0.3 0.0104 to 6.6471 
HP0185 0 0 1 1 0% 3% 0.3 0.0104 to 6.6471 
HP0115 0 1 1 2 0% 5% 0.2 0.0072 to 3.3005 
 
 
 
 
Appendix 3: Result of H. pylori screening with Madrid serum pools
 
Gene 
symbol 
11 
PDAC 
groups 
PDAC 
% 
8 non-
PDAC 
groups 
non-
PDAC 
% 
Odds 
Ratio 
95% CI 
HP0010 5 45% 1 13% 5.8 0.5249 to 64.8254 
HP1117 2 18% 0 0% 4.5 0.1871 to 106.9660 
HP0874 2 18% 0 0% 4.5 0.1871 to 106.9660 
HP0601 2 18% 0 0% 4.5 0.1871 to 106.9660 
HP1564 4 36% 1 13% 4.00 0.3525 to 45.3860 
HP1492 7 64% 3 38% 2.90 0.4423 to 19.2348 
HP0198 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP0003 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP0477 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP0540 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP1477 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP1454 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP1251 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP0797 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP1223 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP0065 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP0608 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP1091 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP1341 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP0518 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP0129 1 9% 0 0% 2.40 0.0873 to 67.5775 
HP0582 6 55% 3 38% 2.00 0.3115 to 12.8400 
HP1226 7 64% 4 50% 1.75 0.2746 to 11.1523 
HP1238 2 18% 1 13% 1.50 0.1160 to 20.8553 
HP1068 2 18% 1 13% 1.50 0.1160 to 20.8553 
HP0537 10 91% 7 88% 1.40 0.0759 to 26.8967 
HP1030 6 55% 4 50% 1.20 0.1935 to 7.4408 
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HP1453 3 27% 2 25% 1.12 0.1407 to 8.9951 
HP0547 3 27% 2 25% 1.12 0.1407 to 8.9951 
HP0118 1 9% 1 13% 0.70 0.0372 to 13.1794 
HP0384 1 9% 1 13% 0.70 0.0372 to 13.1794 
HP0516 2 18% 2 25% 0.66 0.0727 to 6.1110 
HP1125 4 36% 4 50% 0.57 0.0897 to 3.6416 
HP0638 10 91% 8 100% 0.41 0.0148 to 11.4578 
HP0245 6 55% 6 75% 0.40 0.0545 to 2.9332 
HP0371 8 73% 7 88% 0.38 0.0319 to 4.5497 
HP0294 2 18% 3 38% 0.37 0.0455 to 3.0148 
HP1199 2 18% 3 38% 0.37 0.0455 to 3.0148 
HP0011 4 36% 5 63% 0.34 0.0520 to 2.2611 
HP1052 1 9% 2 25% 0.30 0.0222 to 4.0600 
HP1350 2 18% 4 50% 0.22 0.0282 to 1.7541 
HP1293 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP1205 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0751 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0079 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP1343 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0170 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0912 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0514 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0318 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0193 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0690 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0561 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP1119 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP1014 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0788 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0234 0 0% 1 13% 0.21 0.0078 to 6.0750 
HP0875 1 9% 3 38% 0.16 0.0136 to 2.0404 
HP1285 1 9% 3 38% 0.16 0.0136 to 2.0404 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
Appendix 4: Result of HVT screening with Heidelberg serum pools 
 
Gene 
symbol 
10 
PDAC 
10 
CP 
10 
healthy 
PDAC 
%   
non-
PDAC 
% 
Odds 
Ratio 
95% CI 
HVT059 2 0 0 20% 0 12.05 0.5220 to 278.5872 
HVT062 1 0 0 10% 0 6.47 0.2407 to 174.0878 
HVT079 1 0 0 10% 0 6.47 0.2407 to 174.0878 
 
 
Appendix 5: Result of HVT screening with Heidelberg serum individuals 
 
Gene 
symbol 
74 
PDAC 
PDAC 
% 
non-
PDAC% 
Odds 
Ratio 
95% CI 
HVT079 9 12% 0% 13.5 0.7659 to 237.5641 
HVT059 8 10.8% 0% 11.9 0.6695 to 211.0694 
HVT032 7 9.5% 0% 10.3 0.5760 to 185.37 
HVT062 7 9.5% 0% 10.3 0.5760 to 185.38 
HVT017 3 4.1% 0% 4.6 0.2298 to 90.1814 
HVT022 3 4.1% 0% 4.6 0.2298 to 90.1815 
HVT065 2 2.7% 0% 3.2 0.1506 to 68.3041 
HVT006 2 2.7% 0% 3.2 0.1506 to 68.3042 
HVT024 2 2.7% 0% 3.2 0.1506 to 68.3043 
HVT034 2 2.7% 0% 3.2 0.1506 to 68.3044 
HVT044 2 2.7% 0% 3.2 0.1506 to 68.3045 
HVT046 2 2.7% 0% 3.2 0.1506 to 68.3046 
HVT051 2 2.7% 0% 3.2 0.1506 to 68.3047 
HVT021 2 2.7% 0% 3.2 0.1506 to 68.3048 
HVT009 1 1.4% 0% 1.9 0.0757 to 47.5817 
HVT010 1 1.4% 0% 1.9 0.0757 to 47.5818 
HVT011 1 1.4% 0% 1.9 0.0757 to 47.5819 
HVT013 1 1.4% 0% 1.9 0.0757 to 47.5820 
HVT015 1 1.4% 0% 1.9 0.0757 to 47.5821 
HVT020 1 1.4% 0% 1.9 0.0757 to 47.5822 
HVT025 1 1.4% 0% 1.9 0.0757 to 47.5823 
HVT029 1 1.4% 0% 1.9 0.0757 to 47.5824 
HVT030 1 1.4% 0% 1.9 0.0757 to 47.5825 
HVT039 1 1.4% 0% 1.9 0.0757 to 47.5826 
HVT041 1 1.4% 0% 1.9 0.0757 to 47.5827 
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Appendix 6: Serum samples for H. pylori screening 
 
ID Kennung Alter Geschlecht Klassifikation Herkunft Histologie_Klinik Tumorhistologie (IPMN old classif) 
1 Se0001 51 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
2 Se0002 52 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
3 Se0003 48 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
4 Se0004 43 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
5 Se0005 22 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
6 Se0006 19 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
7 Se0007 42 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
8 Se0008 65 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
9 Se0009 39 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
10 Se0010 40 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
11 Se0011 23 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
12 Se0012 33 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
13 Se0013 54 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
14 Se0014 48 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
15 Se0015 59 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
16 Se0016 37 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
17 Se0017 60 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
18 Se0018 34 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
19 Se0019 59 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
20 Se0020 49 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
21 Se0021 47 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
22 Se0022 27 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
23 Se0023 40 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
24 Se0024 43 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
25 Se0025 47 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
26 Se0026 54 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
27 Se0027 22 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
28 Se0028 50 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
29 Se0029 53 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
30 Se0030 52 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
231 Se0219 66 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
232 Se0220 76 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
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233 Se0221 72 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
234 Se0222 72 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
235 Se0223 67 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
236 Se0224 79 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
237 Se0225 69 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
238 Se0226 82 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
239 Se0227 72 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
240 Se0228 51 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
241 Se0229 74 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
242 Se0230 70 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
243 Se0231 62 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
244 Se0232 69 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
245 Se0233 53 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
246 Se0234 77 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
247 Se0235 69 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
248 Se0236 67 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
249 Se0237 82 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
250 Se0238 76 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
251 Se0239 62 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
252 Se0240 69 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
253 Se0241 52 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
254 Se0242 78 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
255 Se0243 70 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
256 Se0244 67 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
257 Se0245 54 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
258 Se0246 63 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
259 Se0247 48 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
260 Se0248 69 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
73 Se0073 22 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
74 Se0074 58 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
75 Se0075 74 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
76 Se0076 47 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
77 Se0077 50 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
78 Se0078 40 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
79 Se0079 49 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
79 
 
80 Se0080 59 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
81 Se0081 53 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
82 Se0082 67 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
83 Se0083 58 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
84 Se0084 51 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
85 Se0085 50 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
86 Se0086 56 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
87 Se0087 41 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
88 Se0088 41 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
89 Se0089 49 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
90 Se0090 52 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
91 Se0091 39 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
92 Se0092 52 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
93 Se0093 43 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
94 Se0094 54 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
95 Se0095 37 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
96 Se0096 39 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
97 Se0097 49 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
98 Se0098 42 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
99 Se0099 45 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
100 Se0100 50 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
101 Se0101 53 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
103 Se0103 44 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
104 Se0104 55 w CP Uni Heidelberg Chronische  
Pankreatitis 
kein Tumor 
105 Se0105 74 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
106 Se0106 78 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
107 Se0107 43 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
108 Se0108 24 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
109 Se0109 62 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
110 Se0110 53 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
111 Se0111 59 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
112 Se0112 76 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
508 Se0508 65 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
509 Se0509 42 w CP 
Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
510 Se0510 45 m CP Uni Heidelberg 
Chronische 
Pankreatitis 
kein Tumor 
511 Se0511 32 m CP Uni Heidelberg 
Chronische 
Pankreatitis 
kein Tumor 
512 Se0512 69 m CP Uni Heidelberg 
Chronische 
Pankreatitis 
kein Tumor 
513 Se0513 54 m CP Uni Heidelberg 
Chronische 
Pankreatitis 
kein Tumor 
514 Se0514 37 w CP Uni Heidelberg 
Chronische 
Pankreatitis 
kein Tumor 
515 Se0515 47 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
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516 Se0516 55 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
517 Se0517 49 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
518 Se0518 54 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
519 Se0519 61 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
520 Se0520 49 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
521 Se0521 59 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
522 Se0522 29 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
523 Se0523 64 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
524 Se0524 44 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
525 Se0525 55 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
526 Se0526 42 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
527 Se0527 52 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
457 Se0457 56 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
458 Se0458 72 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
459 Se0459 51 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
460 Se0460 77 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
461 Se0461 74 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
462 Se0462 73 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
463 Se0463 42 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
464 Se0464 63 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
465 Se0465 52 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
466 Se0466 63 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
467 Se0467 67 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
468 Se0468 62 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
469 Se0469 69 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
470 Se0470 56 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
471 Se0471 63 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
472 Se0472 64 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
473 Se0473 81 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
474 Se0474 61 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
475 Se0475 76 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
476 Se0476 64 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
477 Se0477 70 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
479 Se0479 79 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
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480 Se0480 82 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
481 Se0481 66 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
482 Se0482 60 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
483 Se0483 58 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
484 Se0484 72 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
485 Se0485 70 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
486 Se0486 63 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
487 Se0487 78 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
488 Se0488 57 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
489 Se0489 72 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
490 Se0490 47 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
491 Se0491 85 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
492 Se0492 78 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
493 Se0493 80 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
494 Se0494 70 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
495 Se0495 53 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
496 Se0496 72 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
497 Se0497 75 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
498 Se0498 50 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
499 Se0499 62 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
500 Se0500 76 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
501 Se0501 76 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
502 Se0502 62 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
503 Se0503 76 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
504 Se0504 76 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
505 Se0505 50 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
506 Se0506 50 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
507 Se0507 58 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
560 Se0560 79 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
561 Se0561 58 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
562 Se0562 56 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
563 Se0563 72 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
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564 Se0564 69 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
565 Se0565 78 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
566 Se0566 58 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
567 Se0567 65 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
568 Se0568 76 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
569 Se0569 63 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
570 Se0570 70 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
571 Se0571 61 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
572 Se0572 77 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
573 Se0573 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
574 Se0574 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
575 Se0575 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
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Appendix 7: Serum samples for HVT screening 
 
ID Kennung Alter Geschlecht Klassifikation Herkunft Histologie_Klinik Tumorhistologie (IPMN old classif) 
1 Se0001 51 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
2 Se0002 52 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
3 Se0003 48 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
4 Se0004 43 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
5 Se0005 22 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
6 Se0006 19 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
7 Se0007 42 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
8 Se0008 65 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
9 Se0009 39 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
10 Se0010 40 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
11 Se0011 23 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
12 Se0012 33 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
13 Se0013 54 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
14 Se0014 48 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
15 Se0015 59 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
16 Se0016 37 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
17 Se0017 60 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
18 Se0018 34 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
19 Se0019 59 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
20 Se0020 49 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
21 Se0021 47 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
22 Se0022 27 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
23 Se0023 40 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
24 Se0024 43 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
25 Se0025 47 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
26 Se0026 54 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
27 Se0027 22 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
28 Se0028 50 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
29 Se0029 53 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
30 Se0030 52 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
231 Se0219 66 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
232 Se0220 76 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
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233 Se0221 72 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
234 Se0222 72 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
235 Se0223 67 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
236 Se0224 79 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
237 Se0225 69 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
238 Se0226 82 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
239 Se0227 72 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
240 Se0228 51 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
241 Se0229 74 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
242 Se0230 70 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
243 Se0231 62 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
244 Se0232 69 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
245 Se0233 53 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
246 Se0234 77 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
247 Se0235 69 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
248 Se0236 67 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
249 Se0237 82 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
250 Se0238 76 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
251 Se0239 62 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
252 Se0240 69 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
253 Se0241 52 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
254 Se0242 78 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
255 Se0243 70 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
256 Se0244 67 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
257 Se0245 54 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
258 Se0246 63 w healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
259 Se0247 48 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
260 Se0248 69 m healthy Blutspendedienst 
Mannheim 
healthy kein Tumor 
528 Se0528 49 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
529 Se0529 64 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
530 Se0530 44 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
531 Se0531 45 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
532 Se0532 56 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
533 Se0533 77 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
534 Se0534 66 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
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535 Se0535 42 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
537 Se0537 41 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
538 Se0538 43 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
539 Se0539 69 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
540 Se0540 49 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
541 Se0541 47 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
542 Se0542 50 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
543 Se0543 64 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
544 Se0544 45 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
545 Se0545 39 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
546 Se0546 41 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
547 Se0547 42 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
548 Se0548 56 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
549 Se0549 50 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
550 Se0550 73 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
551 Se0551 63 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
552 Se0552 61 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
553 Se0553 40 w CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
554 Se0554 46 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
555 Se0555 63 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
556 Se0556 70 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
557 Se0557 48 m CP Uni Heidelberg Chronische 
Pankreatitis 
kein Tumor 
558 Se0558 42 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
576 Se0576 60 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
577 Se0577 60 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
578 Se0578 60 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
579 Se0579 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
580 Se0580 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
581 Se0581 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
582 Se0582 79 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
583 Se0583 79 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
584 Se0584 79 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
585 Se0585 66 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
586 Se0586 66 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
587 Se0587 67 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
588 Se0588 69 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
589 Se0589 56 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
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590 Se0590 71 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
591 Se0591 44 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
592 Se0592 70 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
593 Se0593 59 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
594 Se0594 75 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
595 Se0595 70 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
596 Se0596 80 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
597 Se0597 59 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
598 Se0598 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
599 Se0599 44 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
600 Se0600 63 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
601 Se0601 60 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
602 Se0602 75 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
603 Se0603 79 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
604 Se0604 54 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
605 Se0605 83 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
607 Se0607 51 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
608 Se0608 64 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
609 Se0609 51 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
610 Se0610 80 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
611 Se0611 64 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
612 Se0612 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
613 Se0613 58 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
614 Se0614 62 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
615 Se0615 50 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
616 Se0616 58 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
618 Se0618 83 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
619 Se0619 62 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
620 Se0620 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
622 Se0622 64 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
623 Se0623 62 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
624 Se0624 64 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
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625 Se0625 50 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
626 Se0626 66 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
627 Se0627 60 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
628 Se0628 58 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
629 Se0629 51 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
630 Se0630 63 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
631 Se0631 57 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
632 Se0632 83 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
633 Se0633 62 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
634 Se0634 83 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
635 Se0635 50 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
636 Se0636 64 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
637 Se0637 64 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
638 Se0638 62 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
639 Se0639 60 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
640 Se0640 50 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
641 Se0641 51 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
642 Se0642 51 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
643 Se0643 52 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
644 Se0644 51 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
645 Se0645 64 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
646 Se0646 64 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
647 Se0647 60 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
648 Se0648 51 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
649 Se0649 60 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
650 Se0650 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
651 Se0651 51 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
652 Se0652 58 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
653 Se0653 62 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
654 Se0654 62 w PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
655 Se0655 57 m PDAC Uni Heidelberg Pankreastumor Adenocarcinom ductal (auch 
szirrhöses) 
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Appendix 8: Serum pools for H. pylori screening from Madrid 
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